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Cyst reduction in a first-in-kind Drosophila model of polycystic kidney disease 
Cassandra Millet-Boureima 
Polycystic kidney disease (PKD) is an incurable degenerative disease affecting 12.5 
million people worldwide. Numerous cysts form in the renal tubules, which progressively 
enlarge and damage the surrounding kidney tissues, severely reducing quality of life and leading 
most patients to kidney failure with the need for dialysis or transplant. Partly due to lack of 
knowledge of the precise PKD pathological mechanisms, therapeutic options are limited. The 
complex anatomy of the human and vertebrate kidney makes it difficult to define the PKD 
mechanisms and perform drug discovery. In contrast, the fruit fly Drosophila melanogaster 
shares high genetic conservation with humans and features anatomically isolated Malpighian 
(renal) tubules with physiologically diversified regions, making it an ideal model for studying 
renal cystogenesis and performing rapid drug discovery in vivo. One mimic of the second 
mitochondria-derived activator of caspases (Smac), a class of pro-apoptotic molecules being 
developed for cancer therapy, was found to reduce renal cysts in a murine ADPKD model. Here, 
we used our first-in-kind Drosophila PKD model, the Bicaudal C mutant, to test the cyst-
reducing properties of four novel Smac mimics. Smac mimicry was found to decrease the overall 
incidence of tubular cysts. Intriguingly, cysts were reduced at different rates along the 
Malpighian tubules, underscoring functional differences in the tubular regions. Thus, this study 
suggests novel hypotheses on the conservation of renal cystic mechanisms and the function of 
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Chapter 1: Introduction 
My thesis describes the use of the fruit fly Drosophila melanogaster to model renal 
disease. Specifically, I tested in vivo the anti-cystic effects of novel antineoplastic mimics of the 
N-terminal of the pro-apoptotic protein Second mitochondria-derived activator of caspases 
(Smac). Using our first-in-kind Drosophila model of Polycystic Kidney Disease (PKD), we have 
found that Smac mimic administration significantly reduced cysts in the Malpighian (renal) 
tubules of Drosophila. Intriguingly, the Smac mimics appeared to affect distinct sections of the 
Malpighian tubules differentially.  
 
1.1 Polycystic Kidney Disease 
Polycystic kidney disease is one of the most common renal degenerative diseases, 
affecting 12.5 million people worldwide with occurrence between 1 in 400 and 1 in 2500 
individuals (1). There is no cure for PKD, with dialysis and kidney transplant being the only 
effective treatments. Although the stages of disease progression and general pathophysiology of 
PKD are well characterized, the mechanisms leading to renal cystogenesis are complex and still 
a mystery. PKD is a renal neoplasia causing the formation of numerous fluid-filled cysts in the 
kidneys and impaired function of the renal tubule, the nephron (Figure 1.1). Cysts only occur in 
about 1% of nephrons, however, their growth progressively damages the surrounding tissue and 
impairs the surrounding nephrons to the point of complete loss of kidney function and eventual 
kidney failure (1). Disease progression is very variable, the reasons for which are unknown. In 
fact, individuals of the same family inheriting the same mutation may have very different rates of 
kidney degeneration (1). 
 
Figure 1.1 Kidney from a PKD patient. PKD 
causes multiple renal cysts and severe kidney 
enlargement. The picture was provided by our 
collaborator Dr. Albino Eccher, Department of 
Diagnostics and Public Health, University and 
Hospital Trust of Verona, Italy.  
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1.1.1. Genetics and pathways of PKD. The autosomal dominant form of PKD (ADPKD) is 
caused primarily by mutations in the PKD1 (~80%) or PKD2 (~15%) genes, while the recessive 
form (ARPKD) is caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) 
gene (1). PKD1 encodes polycystin 1 (PC1), a large integral membrane protein and G-protein 
coupled receptor that is involved in ion transport, calcium (Ca2+) signaling, and mechanistic 
target of rapamycin (mTOR, also called mammalian TOR) regulation (1-3). PKD2 encodes 
polycystin 2 (PC2), a nonselective Ca2+ channel part of the transient receptor potential family of 
ion channels (1,3). PC1 and PC2 are distributed throughout the cell and a subset of the cellular 
pool is found in a PC1-PC2 complex. Such interaction is thought to play a role in primary cilia 
(1), and intracellular Ca2+ regulation (3). Several other genes have been associated with the onset 
of renal cysts. In ADPKD, mutations in other genes account for about 5% of the cases. Directly 
relevant for the research presented in this thesis, one gene implicated in PKD pathogenesis is 
Bicaudal C (called BICC1 in humans, Bicc1 in mice, and BicC Drosophila). BicC is an 
evolutionarily conserved RNA binding protein first discovered in Drosophila as a negative 
regulator of mRNA translation during oogenesis and early embryogenesis (4,5) which will be 
described in Section 1.2.1. 
Several cellular defects are associated with PKD, such as changes in apical-basal and 
planar cell polarity, fluid transport, and, focus of this thesis, proliferation (1,6). Cystic cell 
growth and proliferation have been associated with the simultaneous disruption of several 
cellular pathways. Reduced intracellular Ca2+ signaling, increased cyclic adenosine 
monophosphate (cAMP) levels leading to abnormal activation of the RAS-RAF-ERK 
(respectively Rat sarcoma, rapidly accelerated fibrosarcoma, and extracellular signal-regulated 
kinase) pathway, as well as higher levels of epidermal growth factor receptor (EGFR) signaling 
are all thought to contribute to cystic growth and proliferation (1). Conversely, increasing Ca2+ 
concentrations raised Akt activity and blocked cAMP-dependent cystic cell proliferation (7). 
Additional pathways involved in PKD cystogenesis include the mTOR, Janus-family tyrosine 
kinase-signal transducer and activator of transcription (JAK-STAT), and Protein Kinase A 
pathways (1). Higher-than-normal levels of the c-Myc protein, encoded by the c-myc 
protooncogene often upregulated in cancer, have been found in both ARPKD and ADPKD (8-
10). Compared to normal wild-type, ARPKD mice exhibited a two- to six-fold and 25- to 30-fold 
increase in c-myc mRNA levels at two and three weeks of age, respectively (8). In a previous 
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study, it was shown that c-myc overexpression (through a SV40 enhancer, β-globin promoter, 
and c-myc gene construct) could induce abnormal proliferation of renal epithelial cells and PKD 
in transgenic mice (9). c-myc overexpression reproduced two ADPKD features in apparent 
contrast with one another, the simultaneous increase of cell proliferation and apoptosis, that has 
been proposed to fuel cyst growth and tissue remodeling respectively (10). Moreover, it has been 
suggested that the local mechanical stress imposed by enlarging cysts may induce apoptosis of 
neighbouring renal epithelial cells (11). Ciliary dysfunction of renal epithelial cells was also 
thought to be important in the cystic process because the polycystin proteins PC1 and PC2 are in 
part co-localized to the primary cilium and primary cilia are functionally linked to several 
pathways implicated in PKD progression such as intracellular Ca2+ and cAMP signaling, growth 
factor regulation, and mTOR (12-15). Thus, PKD has historically been classified as a ciliopathy 
(16). Notably, PC1 and PC2 localize to numerous cellular locales besides the cilium (1), which 
implies complex functionality. While PC1 and PC2 functions are poorly understood, it has been 
proposed that in normal healthy kidneys they may inhibit cystogenesis through their ciliary 
function. However, surprising new evidence has shown that the absence of cilia in Pkd1 mice 
slowed disease progression (1,17), instead of accelerating it as it was expected from the 
“ciliopathy” model (16). Thus, our understanding of the relationship between cilia and PKD is 
evolving. 
 
1.1.2. PKD therapy. Although there is no cure for PKD, multiple strategies to modify the 
affected pathways have been attempted. The accidental discovery that targeting the mTOR 
pathway may have therapeutic potential occurred because of a peculiar type of kidney 
transplantation surgery. In this type of surgery, the affected kidneys are left in place and the 
(third) transplanted kidney is added. When rapamycin was used as an immunosuppressant for 
ADPKD patients who received such a kidney transplant (18), the post-operatory check-ups 
revealed that the affected kidneys had considerably improved, shrinking their overall and cystic 
size (2). Rapamycin displays antiproliferative properties and was found to greatly reduce PKD 
progression by slowing tubular epithelial cell proliferation. However, these effects were 
temporary (2,19-22). Rapamycin inhibits mTOR (23). Thus, several mTOR inhibitors were 
tested as potential PKD therapeutics in various animal models (2,21,24-26). While mTOR 
inhibitors appeared promising in PKD animal models, they did not display therapeutic potential 
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in the clinic, where they only partially slowed kidney growth in ADPKD patients, yet the 
progression of renal function degeneration remained unaltered (24,25). As well, several adverse 
effects were found in patients taking rapamycin or derivatives, including anemia, leukopenia, 
stomatitis, and diarrhea (24,25). Because cystic growth in PKD can be considered a neoplasia 
(27,28), several antineoplastics originally developed as anti-cancer drugs have been tested as 
PKD therapeutics. However, most are proving to be of limited applicability in PKD because of 
long-term toxicity.  
A treatment showing promise in a PKD mouse model is the use of glucose analogs to 
reduce renal cysts (29). It was found that Pkd1-/- mice and microarrays from ADPKD patients 
both exhibit enhanced glycolysis compared to normal controls (29). Reminiscent of cancer cells 
(30), Pkd1-/- cells seemed to depend on aerobic glycolysis for their energy needs to fuel cellular 
growth and proliferation (29). Supporting this model, when glucose levels were depleted, cystic 
cells resumed to wild-type-level proliferation (29). Strongly suggesting that glucose deprivation 
reduces cystic cell proliferation while preserving wild-type cells, cystic cells displayed higher 
apoptotic rates in Pkd1-/- mice, whereas Pkd1+/+ cells activated cell autophagy to survive (29). 
Treatment with 2-deoxyglucose, a non-metabolizable glucose analog, led to a reduced cyst 
number (called cystic index) without affecting other organs or the overall body weight. Two-
deoxyglucose is being used in combination therapy to treat osteosarcomas and lung cancers in 
phase 2 clinical trials (31). With such encouraging preliminary results, 2-deoxyglucose is one 
candidate combination drug in PKD therapeutics (29).  
As mentioned in Section 1.1.1, EGFR signaling is upregulated in PKD. Src is an 
important mediator of EGFR activation (32). Consistently, Src overexpression correlated with 
enlarged cystic kidneys from murine models of ARPKD (32). Therefore, one group sought to 
target this pathway by using Src inhibitor, SKI-606 (32). SKI606 administration to BPK mice 
(ARPKD model) significantly reduced both kidney size and renal cysts (32). Moreover, no renal 
toxicity was observed after 20 days of treatment and a dose of 30 mg/kg/day. Surprisingly, Src 
inhibition did not lower intracellular cAMP, which is normally elevated together with EGFR 
(32). This indicated that the observed kidney improvements were notably independent of cAMP 
(32), further highlighting how complex EGFR in vivo signaling and PKD pathophysiology are. 
Contingent on the pending results of long-term toxicity studies, the observed drug tolerability 
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and promising cyst reduction in murine models (32) suggest that Src inhibitors may offer 
potential for PKD therapeutics.  
Currently, the only approved drug for PKD management is tolvaptan, a vasopressin V2 
receptor antagonist already approved for heart disease treatment. Cystic fluid in the kidney is 
thought to arise in part from elevated cAMP concentrations (33). Tolvaptan is believed to inhibit 
V2R, which subsequently reduces cAMP levels in the kidney, thereby reducing cystic fluid 
accumulation and renal epithelial cell growth (33). Tolvaptan was found to be appropriate for 
only a subset of patients who were between the ages of 18 and 50, had fast disease progression, 
and low water and/or high salt intake (34). Tolvaptan reduced the increase in total kidney volume 
and slowed the deterioration of kidney function (35). However, its efficacy appeared to decrease 
during the three years tested and, troublingly, markers of liver toxicity increased (35,36). Unlike 
other treatment options mentioned above, tolvaptan appears to principally target the 
compensatory physiological mechanisms dependent on vasopressin signaling and may affect the 
core PKD cellular pathways indirectly. Thus, safe and effective PKD therapeutics suitable for a 
wider spectrum of patients are needed. 
An additional class of compounds directly relevant for this thesis is being examined to 
reduce cellular proliferation in PKD. Such compounds are mimics of a cellular regulator called 
second mitochondria-derived activator of caspases (Smac) described below.  
 
1.1.3. Smac-dependent regulation. Smac or DIABLO (direct inhibitor of apoptosis-
binding protein with low pI) is a protein that activates a signaling cascade initiated by the 
targeting and ubiquitin-dependent degradation of inhibitors of apoptosis proteins (IAPs). Such 
cascade culminates with pro-apoptotic caspase activation. IAP antagonists were characterized in 
Drosophila, leading to the identification of the Reaper, Head involution defective (Hid) and 
Grim proteins containing an N-terminal ‘RHG’ motif (named after their initials). Despite the lack 
of mammalian orthologs, Reaper, Hid and Grim could induce cell death when expressed in 
mammalian cultured cells, which eventually led to the identification of the mammalian 
Smac/DIABLO protein the first of a few proteins that similarly function through an RHG motif 
(37,38). IAP proteins are found associated to the cytoplasmic side of several receptors. Here, we 
will examine the case of the TNF-α receptor, which is relevant to this thesis. In the presence of 
both TNF-α and a pro-apoptotic signal, Smac/DIABLO is released from the mitochondria 
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(Figure 1.2). Smac then binds IAPs on the cytoplasmic side of the TNF-α receptor complex, 
which leads to their ubiquitination and degradation (39-41). This in turn leads to TNF-α-
mediated activation of caspases and apoptosis (41). Depending on the cellular context and the 
nature of the pro-apoptotic stimulus, the specific cell death pathway may differ. Smac mimicry 
leverages on this regulation by introducing just the RHG domain, e.g. as a peptide, to trigger the 
cascade in the presence of the TNF-α−TNFR interaction. This strategy has been used to induce 
apoptosis preferentially in TNF-α dependent cancer cells and some Smac mimics are currently in 
phase 2 clinical trials (42,43). TNF-α−signaling can also give a pro-survival signal to cells (44), 
an opposing signal from apoptosis seen in cancer and cystic cells.  
 
 
Figure 1.2 Essential Smac-dependent 
regulation pathway. Example of TNF-
α-dependent Smac mechanism is shown. 
Only the main events and factors are 









1.1.3.1. Smac mimicry in PKD. In both ADPKD patients and a Pkd1-/- mouse model, 
cystic fluid was found to contain high amounts of TNF-α (45,46). Cystic cells (but not the 
surrounding non-cystic tubular cells) also overexpress the TNF-α receptor 1 (TNFR1) (46). This 
creates a positive reinforcement of the TNF-α-dependent pro-survival signal between the cystic 
cells and the bathing cystic fluid, which is supposed to promote cyst growth (46). Potential 
contributions of the less studied TNF receptor TNFR2 are unknown. Similar to cancer, Smac 
mimicry can potentially be used to interfere with cystic cell proliferation. Based on these 
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considerations, the Smac-mimetic GT13072 was used to interfere with such cyst survival signal 
and induce cystic cell death in a TNF-α-dependent manner (46). This strategy aims to 
specifically target cystic cells (bathed in TNF-α-containing cystic fluid), while sparing the 
adjacent tubular cells in non-cystic regions (that do not accumulate TNF-α-containing fluid). 
Experiments on a murine PKD model suggest that when a Smac mimic is present, the TNF-α 
“pro-survival complex I” is disrupted and a “pro-death complex II” is, instead, formed as follows 
(Figure 1.3). Briefly, the Smac mimic targets cIAPs for ubiquitination and degradation, which 
leads to the dissociation of the pro-survival complex I (composed of TRADD, RIPK1, TRAF2, 
cIAP1 and cIAP2); then RIPK1, FADD and caspase-8 form the pro-death complex II (Figure 
1.3). The latter subsequently activates downstream effector caspase-3 and apoptosis is initiated.  
 
 
Figure 1.3 TNF-α  dependent regulation in PKD and Smac mimicry. In ADPKD, cystic cells 
display upregulated TNF-α and TNFR. High TNF-α-TNFR signaling confers pro-survival 
signals through complex I (left). Introducing Smac mimics is thought to target cIAP and 
disassemble complex I, which causes the formation of pro-death complex II, and induce 
apoptosis (right). See text for more detail. 
 
1.1.4. Conservation of the TNF pathway in Drosophila. The Drosophila genome contains two 
TNF orthologs, called Eiger and Darth (47-50) and two TNFR orthologs, called Wengen and 
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Grindenwald (48,50-52). Eiger and Wengen are thought to function together, similar to the 
mechanism of action of mammalian TNF-α and its receptors. Much less in known about the 
functions of the Darth and Grindelwald proteins. As well, how TNF and TNF signaling may 
contribute to the function of the Malpighian tubule is unknown. Drosophila orthologs of FADD, 
TRAF and IAP also exists and have been in part characterized in other epithelia (48). Because 
components of the TNF signaling appeared to be conserved in Drosophila, and the RHG-
containing Reaper Hid and Grim can function in mammalian cells (53), we tested if Smac 
mimicry could also reduce cysts in the Drosophila PKD model.  
 
1.2 Modeling PKD in Drosophila 
The anatomical complexity of the human and vertebrate kidney makes it difficult to study 
and probe it genetically (54). Genetic tractability refers to organisms and systems amenable to 
genetic manipulation. Therefore, the vertebrate kidney has been defined “relatively genetically 
intractable” (55), which complicates the study of the genetic underpinning of several pathologies. 
Drosophila melanogaster is useful to model vertebrate development and the molecular/cellular 
mechanisms of fundamental biological disease processes due to a 75% conservation of human 
disease pathways (56). Its genetic tractability enables studies of disease mechanisms. Moreover, 
Drosophila is inexpensive to culture in the laboratory and yields large populations for robust 
statistical analyses. Its short lifespan facilitates monitoring of the temporal progression of normal 
and diseased phenotypes. The large genetic toolkit for Drosophila research enables multiple 
rounds of experiments needed to refine mechanistic models. Specific to the renal system, 
Drosophila possesses two pairs of Malpighian tubules freely floating in the abdomen, that are 
analogous to the tubular part of the human nephron, as well as nephrocyte clusters separately 
located in the body cavity that are analogous to human renal podocytes in the glomerulus (57). 
Unlike vertebrate nephrons, Drosophila Malpighian (renal) tubules can be effectively micro-
dissected enabling precise analyses. Important for the research presented here, a conserved 
feature of the Malpighian tubules is that distinct regions along the tubules carry out different 
functions, similar to the human nephron. Because the Malpighian tubules are anatomically 
separated, rather than embedded in an organ, they do not rely on salt gradients for urine 
concentration. The Drosophila small body size, short tubules and high transport rates all 
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contribute to proper urine concentration (detailed in Appendix II). Drosophila melanogaster has 
been successfully used to model human renal function (57).  
Our laboratory has developed the first Drosophila PKD model. Similar to PKD, the 
cystic Drosophila exhibit renal cysts all along their Malpighian tubules, have impaired renal 
function, and display myc over-expression and mTOR activation (58). The cystic Drosophila 
model also displayed conserved pharmacological response to rapamycin (58). The cystic D. 
melanogaster used here carry mutations in the BicC gene, which encodes a conserved RNA-
binding protein, described in Section 1.2.1. Notably, mutations in BicC orthologs in vertebrates, 
including humans, cause renal cysts (5,59,60).  
 
1.2.1. BicC genetics. BicC was discovered in a genetic screen for maternal regulators of 
embryonic polarity (4,5). Oocytes from heterozygote BicC females were found to have disrupted 
anterior-posterior axis determination and yield embryos displaying various degrees of loss-of-
segments phenotypes, including so-called “bicaudal” embryos consisting of two posterior ends 
juxtaposed in a mirror-image fashion (4,5). Homozygote BicC females, instead, exhibit 
oogenesis arrest at stage 10 (61). In the ovary, the BicC protein functions as a translational 
repressor for several mRNAs, including its own (5,62,63). On the other hand, BicC is 
ubiquitously expressed and it is unknown how it functions in somatic tissues (5). We have shown 
for the first time that BicC homozygote Drosophila develop cysts in the Malpighian tubules and 
display crucial PKD features (58). BicC is relevant for PKD, because we have found that BicC is 
genetically downstream of PKD1 (58). In fact, the human BICC1 mRNA was significantly 
downregulated in microarrays from cysts of PKD1-type ADPKD patients (58). Moreover, in the 
kidneys of Pkd1-/- mice the Bicc1 protein was significantly reduced (58). These results, 
combined with the fact that mutations of the BicC orthologs in several vertebrates (mice, 
Xenopus, zebrafish, humans) cause renal cysts, strongly suggest that BicC may be a key 
regulator of renal homeostasis and its mutation eventually results into cyst formation. Thus, the 
BicC mutant Drosophila can be used to model the aspects of PKD phenotypes due to BicC loss-
of-function (58). Because of the BicC ovarian function, BicC homozygote Drosophila are sterile; 
thus, BicC mutants must be obtained by crossing heterozygotes for BicC alleles in trans to the 
CyO balancer.  
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1.3 Thesis Overview 
 My thesis consists of a published article reporting on the in vivo anti-cystic effects of four 
novel small molecule Smac mimics (64). The Smac mimics used here displayed proliferation-
modulating properties in cancer cells (65) and were synthesized by our collaborators Dr. Ramesh 
Chingle and Dr. William D. Lubell from the Chemistry Department at the Université de 
Montreal. The Smac mimics were chosen in part as proof-of-principle for feasibility of drug 
discovery and development in Drosophila because of the precedent mentioned in Section 1.1.3.1, 
in which the Smac mimic and birinapant analog GT13072 could reduce cysts in a murine PKD 
model (46). The four Smac mimics (also called analogs) included the natural four-amino acids 
found at the N-terminal of the Smac protein, the sequence Alanine-Valine-Proline-Isoleucine 
(AVPI). Three analogs were /0/1213"4256!"7!89":9!7"3;<=27!;21>/:24!392!α?:/;@<7!<A!<72!<;!B<;2!<A!392!/B"7<!/:"4!;25"4C25!8"39!:<752DC27:25!<7!392!1213"42!:<7A<;B/3"<76!/:3"#"3E!/74!19/;B/:<F"723":!1;<12;3"25!(66). Structure-activity relationship revealed differential cyst-
reducing activity of the of the four Smac mimics. Intriguingly, the different regions of the 
Malpighian tubules responded differentially to Smac mimicry, which was never observed in 
vertebrates, likely due to the kidney anatomical complexity. Such differential response has 
potential relevance in functional studies of Malpighian tubule function in Drosophila. If 
conserved to humans, a differential pharmacological response of the renal tubule may eventually 










Chapter 2: Cyst reduction in a Polycystic Kidney Disease Drosophila 
Model Using Smac Mimics 
 
Introduction to Chapter 2: The following research article reports the anti-cystic effects of 
Smac mimicry using our first-in-kind Drosophila model of PKD and novel Smac mimics 
synthesized from collaborating Lubell laboratory. This undertaking was a proof-of-principle 
investigation to validate drug-screening protocols in adult Drosophila using peptide and peptide 
analogs. Considering that TNF pathway components and the activity of RHG-domain containing 
proteins appear conserved from humans to Drosophila, these tests also served to probe if the 
cystic BicC mutants responded to Smac mimicry, similar to the PKD murine model.  
 
Article summary and importance.  
To test anti-cystic activity of the Smac mimics, populations of sibling BicC mutant 
Drosophila were probed in parallel by administering orally either Smac mimics or the solvent in 
which compounds were dissolved (vehicle) and in otherwise identical setups. Initial time course 
was performed to identify effective time of administration. Similarly, a dose-response was 
performed to identify effective compound concentration. To determine if the Smac mimics 
influenced cyst development, I established an assay based on the cystic index used in PKD 
research where cysts were scored based on the size of tubule dilation (e.g., (29), also see section 
1.1.2). The Drosophila Malpighian tubules can be examined in their entirety both overall and 
regionally. Therefore, cysts were recorded from 50 individuals per condition after 20 days of 
either Smac or vehicle treatment, assigned to the Malpighian tubule regions and analyzed 
statistically. Two allelic combinations for BicC, BicC !/YC33 (yielding milder cystic defects) and 
BicC !/IIF34 (yielding stronger cystic defects) were used. These two combinations were used as a 
mini allelic series to test the differential activities of the compounds in the mild and more severe 
BicC mutant phenotypes, similar to our previous research (58). The Smac mimics used were: 
peptide 1, the natural Smac N-terminal four-residue sequence AVPI and three derived azapeptide 
mimics where the α-carbon(s) of one or more amino acids were replaced by nitrogen featured 
constrained structures. These were named mimic 2-4 (64). Peptide 1, mimics 2 and 3 displayed 
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anti-cancer activity in breast cancer cells (66). Mimic 4 was a new molecule with modifications 
expected to improve its stability in vivo.   
This research is important because it validated usefulness of the Drosophila BicC PKD 
model for drug discovery, it indicated activity of four Smac mimics that have never been used in 
PKD therapy, which extends and further confirms prior work from Fan and colleagues in the 
mouse (46) and further corroborated therapeutic potential for Smac mimicry in PKD. 
 
Note: This article was published as “Millet-Boureima C., Chingle R., Lubell W.D., and Gamberi 
C. 2019. Biomedicines, vol. 7(4), 82.” and the entirety of its content is being presented in this 
thesis. To fulfill the request of the committee members, the following edits to the published text 
were made in this thesis: Malpighian tubules are mentioned in extenso; “fly” and “flies” are 
replaced with “Drosophila” or “individuals”, or deleted depending on context; one sentence in 
Section 2.3.2 that recalls a concept detailed in the Experimental Section, has been deleted; a few 
word changes that improve readability, yet do not change the meaning, have also been 
introduced. The published PDF version complete with supplementary files (that were excluded 
from the main body of this thesis) is available in Appendix I and online. DOI.  
 
Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited malady 
affecting 12.5 million people worldwide. Therapeutic options to treat PKD are limited, due in part to 
lack of precise knowledge of underlying pathological mechanisms. Mimics of the second 
mitochondria-derived activator of caspases (Smac) have exhibited activity as antineoplastic agents 
and reported recently to ameliorate cysts in a murine ADPKD model, possibly by differentially 
targeting cystic cells and sparing the surrounding tissue. A first-in-kind Drosophila PKD model has 
now been employed to probe further the activity of novel Smac mimics. Substantial reduction of 
cystic defects was observed in the Malpighian (renal) tubules of treated Drosophila, underscoring 
mechanistic conservation of the cystic pathways and potential for efficient testing of drug prototypes 
in this PKD model. Moreover, the observed differential rescue of the anterior and posterior tubules 
overall, and within their physiologically diverse intermediate and terminal regions implied a nuanced 
response in distinct tubular regions contingent upon the structure of the Smac mimic. Knowledge 
gained from studying Smac mimics reveals the capacity for the Drosophila model to precisely probe 
PKD pharmacology highlighting the value for such critical evaluation of factors implicated in renal 
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function and pathology. 
 
2.1 Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) induces the formation of cysts 
along the entire renal tubule, predominantly at the terminal region and the collector tubule, as 
well as extra-renal manifestations (1). Inherited through a monogenic pattern with the most 
frequent mutations affecting PKD1 or PKD2, ADPKD displays high heterogeneity in both 
phenotype and speed of progression (1). Abnormal proliferation of the epithelial tubular cells 
during development gives rise to cysts prenatally. Cysts become more numerous with age, 
gradually enlarging and filling with fluid (1). Animal models of PKD have been invaluable for 
defining disease progression and identifying key molecular alterations; however, the precise 
mechanisms underlying disease pathology remain to be elucidated at the molecular level (67). 
The most recent addition to the arsenal of PKD animal models has been the fruit fly, Drosophila 
melanogaster. Mutants for the Bicaudal C (BicC) gene (hereby BicC Drosophila) were found to 
recapitulate key molecular features of PKD, including myc over-expression and mechanistic 
target of rapamycin (mTOR) pathway activation (58). Consistent with ADPKD, the BicC 
Drosophila formed cysts along the entire length of the tubule, with higher frequency at the 
intermediate, terminal and collector tubule regions (58). Moreover, analogous to vertebrate PKD 
(2,19,21,68,69), pharmacological treatment of BicC Drosophila with rapamycin transiently 
reduced cysts (58). Consistent with the relevance of the BicC phenotype in PKD, BICC1 mRNA 
and Bicc1 protein orthologues were respectively found to decrease in kidneys from PKD1 
patients and Pkd1-/- mice (58). Thus, PKD1 dysfunction is associated with decreased BicC 
function. 
An excellent model of human renal function, Drosophila has high genetic conservation 
and a streamlined anatomy (reviewed in (57)). In contrast to the human kidney, which contains 
one million tubular filtering units called nephrons, Drosophila harbors two pairs of Malpighian 
tubules, which are functionally equivalent to the tubular portion of the nephron. Suitable to the 
open circulatory system of Drosophila, the renal system does not have glomeruli and possesses 
nephrocytes, which exhibit re-adsorptive function analogous to the human glomerular podocytes 
(57). Originating from the interface between the mid- and hind-gut, the Malpighian tubules are 
asymmetrical with longer tubules anteriorly and shorter ones posteriorly. Reminiscent of the 
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different nephron types in the human kidney, the anterior and posterior Malpighian tubules have 
distinct transcriptomes (70). Like the human renal tubules, Malpighian tubules can be divided 
into distinct regions, which in Drosophila are called proximal, intermediate, and terminal. The 
proximal region excretes fluid into the tubules, the intermediate region secretes potassium 
chloride and water, and the terminal region is responsible for sodium and, possibly, water 
reabsorption (57). One key advantage of the Drosophila renal system is that the Malpighian 
tubules are anatomically distinct, float freely in the body cavity, and can be cleanly micro-
dissected and examined in their entirety. 
Antineoplastic mimics of the second mitochondria-derived activator of caspases (Smac, also 
called the direct inhibitor of apoptosis-binding protein with low pI, DIABLO) have been used to 
sensitize cancer cells to apoptosis by targeting inhibitors of apoptosis proteins (IAPs, (71,72)). 
Highly conserved, IAP proteins play a key role in balancing cell survival and cell death through 
multiple intersecting cellular pathways. Implicated in innate immunity (73,74), IAPs are often 
upregulated in cancer (75). First discovered in insect baculovirus as inhibitors of cellular 
apoptosis which enable viral replication, IAPs were found in both vertebrates and invertebrates 
((76), reviewed in (71)). The best-known mammalian IAPs are X-linked IAP (XIAP), cellular 
IAP1 (cIAP1) and cIAP2 (71). The Drosophila genome encodes four IAPs, Diap1, Diap2, 
dBruce and Deterin (77-79). Multiple proteins have been shown to antagonize IAPs. First 
discovered in Drosophila, three proteins, Reaper (80), Hid, (81) and Grim (82), can induce 
apoptosis when transfected into mammalian cells, which demonstrated functional conservation 
of the apoptotic cellular machinery (53). Additional Drosophila IAP antagonists are Jafrac (83), 
Sickle (84-86) and HtrA2 (87-89). The search for the mammalian IAP antagonists yielded 
Smac/DIABLO (40,90), Omi/HtrA2 (91), apoptosis-related protein in the TGF! signaling 
pathway (ARTS, (92)) and XIAP-associated factor 1 (XAF1, (93)). IAP antagonists function 
through an RHG motif, named after the prototypical Reaper, Hid and Grim Drosophila proteins. 
In the case of the well-studied human Smac/DIABLO and Drosophila Hid IAP antagonists, pro-
apoptotic stimuli induce proteolytic cleavage exposing the RHG motif at the N-terminus enabling 
interaction with IAP proteins (94,95) and triggering their ubiquitination and degradation. In the 
appropriate cellular context, IAP degradation can eventually lead to cell death either by way of 
caspase activation or via tumor necrosis factor (TNF) signaling (71,96,97). The discovery that 
the Smac/DIABLO N-terminal peptide H-Ala-Val-Pro-Ile-NH2 can recapitulate the pro-apoptotic 
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function of the entire protein has inspired the development of various Smac mimics, which 
enable sensitization of neoplastic cells to apoptosis (72). 
Based on the premise that ADPKD is considered in part a neoplastic condition (27,28), and 
that various TNF complex components were upregulated in Pkd1-/- mouse embryonic kidney 
(MEK) cells, the Smac mimic and birinapant analog GT13072 was used to induce TNF-"-
dependent cell death in both cultured cells and a rat model of PKD (46). The pro-apoptotic 
properties of GT13072 were specific for the TNF-positive renal epithelial cystic cells and spared 
surrounding non-cystic cells, offering therapeutic potential to ablate renal cystic cells to delay 
cystogenesis (46). The TNF pathway is highly conserved in Drosophila (47,48,51,52,98,99). The 
capacity for Smac mimics to reduce Malpighian tubule cystogenesis has now been tested in the 
BicC cystic Drosophila. The prototypical H-Ala-Val-Pro-Ile-NH2 (peptide 1, Figure 2.1) and 




Figure 2.1 Second mitochondria-derived activator of caspases (Smac) analogs: peptide 1 and 
mimics 2-4 (Val, aza-residue and modifiend N-terminal in blue). Logarithm of the partition 
coefficient (clogP) values were calculated as described below.   
 
2.2 Experimental Section 
 
2.2.1. Drosophila Lines and Genetics. Drosophila care was previously described in detail (58). 
In brief, Drosophila were grown on cornmeal agar (Jazzmix, Fisher Scientific Canada, Ottawa, 
ON) at 25 °C and aged as indicated. OregonR (OreR) wild-types were maintained as in (58). BicC 
mutants were generated by crossing Df(2L)RA5/CyO (BicC-encompassing deletion obtained 
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from Bloomington Drosophila Stock Center) virgin females with one of the two hypomorphic 
BicC mutations, BicCYC33/CyO and BicCIIF34/CyO and selecting straight-winged progeny 
(Df(2L)RA5/BicCYC33, BicC!/YC33 and Df(2L)RA5/BicCIIF34, BicC!/IIF34). The two BicC allelic 
combinations produced truncated proteins and sterile BicC mutants (58). Eclosed adults were 
collected every two days to yield 0–2-day old populations and aged as described. 
 
2.2.2. In Vivo and Ex Vivo Assays 
2.2.2.1. Cystic Index. For the cyst analysis, 0–2-days old Drosophila were aged seven 
days (i.e., 7–9 days old) and were fed every three days with 2 mL of cornmeal food and equal 
volumes (50 #L) of either vehicle (water) or an aqueous solution containing peptide 1 or Smac 
mimic 2–4. Each compound was used at 20 #M and was administered for 20 days (i.e., until 27–
29 days old). Malpighian tubules were micro-dissected from 25–50 females in phosphate 
buffered saline (PBS) and the number of cysts was scored separately in anterior and posterior 
tubules and assigned to each tubular region (i.e., proximal, intermediate and terminal (57,58)), as 
follows. At one extremity, the proximal region consists of about 15% of the tubule length, tends 
to have an opaque whitish content (posterior tubule), is thinner than adjacent regions (especially 
in the anterior tubule) and often exhibits a slight constriction terminally. The neighboring 
intermediate region has darker contents and consists of about 55% of the tubule length. The 
terminal region is often translucent, directly connected to the collecting tubule, and consists of 
the remaining 30% of the tubule length. Cysts were considered tubular deformations creating 
uni- or bi-laterally protuberant pouches. Extra-branches (as in (58)) were counted as cysts. 
Values were plotted using the Prism 8.0 software (Graphpad Software, San Diego, CA, USA) as 
nested distributions. Statistical analyses were performed as unpaired t tests with Welch’s 
correction (the populations may not have equal standard deviations). The raw data counts are 
listed in supplementary Table S1. 
2.2.2.2. Microscopy. Malpighian tubules from appropriately aged and treated Drosophila 
were micro-dissected in 1$ PBS, equilibrated into a 3:1 1$ PBS:glycerol solution and 
photographed on a Leica MZ FLIII Fluorescence Stereomicroscope with Leica MZ series 
10$/21B Widefield adjustable eyepieces equipped with a Canon DS126201 EOS 5D MARK II 
camera, using visible light. Canon raw files (CR2) were converted into TIF format using the 
Adobe Lightroom 3.2 software (Adobe Systems, San Jose, CA, USA). 
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2.2.3. General Synthetic Methods. Chemicals were used as received from commercial sources 
without further purification unless stated otherwise. All glassware was stored in the oven or 
flame-dried and let cool under an inert atmosphere prior to use. Anhydrous solvents (DCM, and 
DMF) were obtained by passage through solvent filtration systems (Glass-Contour, Irvine, CA, 
USA). Silica gel chromatography was performed using 230–400 mesh silica gel (Silicycle), and 
TLC was on glass-backed silica plates visualizing the developed chromatogram by UV 
absorbance or staining with ceric ammonium molybdate or potassium permanganate solutions. 
Nuclear magnetic resonance spectra (1H and 13C) were recorded on a Bruker AV 500 
spectrometer and referenced to residual solvent in CD3OD (3.31 ppm, 49.0 ppm). Coupling 
constant J values and chemical shifts were measured in Hertz (Hz) and parts per million (ppm). 
Infrared spectra were recorded in the neat on a Perkin Elmer Spectrum One FTIR instrument and 
are reported in reciprocal centimeter (cm–1). Liquid chromatography%mass spectrometry 
(LC%MS) was performed on an Agilent Technologies 1200 series instrument in positive 
electrospray ionization (ESI)-time-of-flight (TOF) mode at the Université de Montréal Mass 
Spectrometry Facility. Sodium and proton adducts ([M + Na]+ and [M + H]+) were used for 
empirical formula confirmation. The peptide H-Ala-Val-Pro-Ile-NH2 (1), Smac mimics 2 and 3, 
and aza-cyclohexylglycinyl-L-proline benzhydrylamide (8), all were synthesized according to 
published methods (65). N-Boc-N-Methyl-L-alanine and diisopropyl ethyl amine (DIEA) were 
purchased from Aldrich or Alfa Aesar and used without further purification. Benzotriazol-1-yl-
oxytripyrrolidino-phosphoniumhexafluoro-phosphate (PyBop) was purchased from GL 
Biochem™, recrystallized prior to use from dry CH2Cl2/Et2O (melting point, 156 °C), and stored 
in the dark. 
N-Methyl alaninyl-aza-cyclohexylglycinyl-L-proline benzhydrylamide (4). A solution of 
aza-cyclohexylglycinyl-L-proline benzhydrylamide (8, 1 eq., 65 mg, 0.155 mmol, prepared 
according to (65)) and DIEA (2 eq., 40 mg, 53 #L, 0.309 mmol) was added to a solution of N-
(tert-butoxycarbonyl)-N-methyl-L-alanine (1.2 eq., 38 mg, 0.186 mmol) and PyBOP (1.5 eq., 
121 mg, 0.233 mmol) in DMF (3 mL), and the mixture was stirred overnight. The volatiles were 
removed under vacuum. The residue was dissolved in EtOAc (10 mL), washed with 5 mL of 
saturated aqueous NaHCO3 and brine (10 mL), dried over Na2SO4, filtered, and evaporated. 
Without further purification, the residue was dissolved in a 25% solution of trifluoroacetic acid 
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in dichloromethane (2 mL) and stirred for 2 h. The volatiles were removed under vacuum. The 
residue was dissolved in CH2Cl2 and the solution was evaporated. The residue was suspended in 
2 mL of 1N HCl, stirred for 30 min, and freeze-dried to give the hydrochloride salt as off white 
solid, which was purified by RP-HPLC on a reverse-phase Gemini® C18 column (Phenomenex® 
Inc., pore size: 110 Å, particle size: 5 µm, 250 x 21.2 mm) using a binary solvent system 
consisting of a gradient of 5–60% MeOH [0.1% formic acid (FA)] in water (0.1% FA) with a 
flow rate of 10.0 mL/min and UV detection at 214 nm. The desired fractions were combined and 
freeze-dried to white fluffy powder: azapeptide 4 (5.2 mg, 0.01 mmol, 7%): mp 93–94 °C; 1H 
NMR (500 MHz, CD3OD) & 8.40 (s, 1H), 7.45–7.20 (m, 10H), 6.24 (s, 1H), 4.56–4.42 (m, 1H), 
4.05–3.88 (m, 1H), 3.69–3.42 (m, 2H), 2.59–2.43 (m, 3H), 2.43–2.31 (m, 1H), 2.26–2.14 (m, 1H), 
2.14–2.00 (m, 1H), 2.00–1.91 (m, 1H), 1.91–1.62 (m, 6H), 1.53–1.36 (m, 5H), 1.35–1.03 (m, 5H); 
13C NMR (125 MHz, MeOD) & 174.1, 171.2, 161.4, 143.2, 139.1, 129.5 (2C), 129.4 (2C), 129.3 
(2C), 128.8 (2C), 128.4, 128.2, 63.6, 57.9, 57.4, 49.6, 31.5, 31.3, 30.8, 26.9, 26.72 (2C), 26.69 
(2C), 26.5, 17.5; IR (neat) vmax/cm-1 2929, 1638, 1532, 1495, 1449, 1406, 1344, 1323, 1095; 
HRMS m/z calculated for C29H40N5O3 [M+H]+ 506.3126; found 506.3139. (Supplementary File 
S1). The logarithm of the partition coefficient (clogP) values were calculated using Chemdraw 




2.3.1. Chemistry. Smac activity has been correlated to binding to IAP proteins and mimicked by 
its N-terminal four-residue amide sequence (H-Ala-Val-Pro-Ile-NH2, 1, Figure 2.3) (100-102). 
The purported turn conformation adopted about the central Val-Pro dipeptide in this sequence 
has led to the synthesis of various constrained analogs, exhibiting enhanced potency (72,103). 
Noting the similar conformational preferences of indolizidinone amino acid and aza-amino acyl 
proline turn mimics (104-107), and the relative ease of synthesis of the latter, a series of aza-
analogs were synthesized and certain were shown to induce cell death by a caspase-9 mediated 
apoptotic pathway in cancer cell cultures (65,106). Notably, aza-methanopipecolate and aza-
cyclohexylglycine analogs 2 and 3 were synthesized using pericyclic chemistry on the diazo 
dicarbonyl moiety of an azopeptide to examine the conformation of the Val residue in 1 
(65,108,109). Specifically, the Alder-ene reaction of cyclohexadiene and the Diels-Alder reaction 
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of cyclopentadiene on N-(Cbz)azoglycinyl-proline benzhydrylamide 5 gave the unsaturated 
azapeptides 6 and 7, which were hydrogenated with concomitant removal of the 
benzyloxycarbonyl group, coupled to N-protected alanine, and deprotected (Scheme 2.1, (65)). 
Considering the tolerance of N-methyl-alanine for alanine in the terminal position (110), a similar 
approach was used to prepare N-methyl analog 4 by hydrogenation of azapeptide 7, coupling of the 
resulting aza-cyclohexylglycinyl-L-proline benzhydrylamide (8) to N-(Boc)-N-methylalanine 
using PyBop and cleavage of the Boc group with TFA in DCM. In cultured MCF7 breast cancer 
cells, aza-cyclohexylglycine analog 3 induced up to 60% cell death relative to vehicle (65). 
 
 
Scheme 2.1 Synthesis of Smac mimics 2 and 4 (dienes, azo- and aza-residues in blue).  
 
2.3.2. Effect of Smac Mimic Administration in vivo. We have previously reported that 
Drosophila mutants in the BicC gene recapitulate key features of PKD (58). Considering that 
Smac mimics showed efficacy at reducing cysts in a rat PKD model (46), the results of Smac 
mimic administration were tested in the BicC cystic Drosophila using two different allelic 
combinations. The BicC!/YC33 combination induces milder cystic defects than the BicC!/IIF34 one 
(58). Straight-winged mutants (BicC!/YC33, BicC!/IIF34) from crosses were selected within two 
days of eclosion to yield pools of 0–2 days old Drosophila and aged for seven days (7–9 days 
old), during which time they were kept well-fed by transferring to fresh vials twice (Figure 2.2). 
Aged siblings were divided into fresh vials containing food spiked with either vehicle (water, 50 
#L) or one of the Smac analogs 1–4 at 20 µM (50 #L). Drosophila were transferred into identical 
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fresh vials every three days. After 20 days of treatment, the Malpighian tubules were micro-
dissected from 27–29 day old mutants and analyzed ex vivo. 
 
Figure 2.2 Testing protocol for Smac-mimic efficacy in cyst reduction. OreR wild-type, 
BicC!/YC33, and BicC!/IIF34 Drosophila (0-2 days old) were placed in food-containing vials at age 
0-2 days and transferred into fresh vials every three days. Once the age of 7-9 days was reached, 
Drosophila were placed in vials containing one of each of the Smac mimics or vehicle control, 
respectively. Cysts were scored on the micro-dissected Malpighian tubules after 20 days, when 
animals reached age 27-29 days. 
 Per each condition, cystic deformities were scored using 25–50 female BicC!/IIF34 and 
BicC!/YC33 Drosophila (i.e., 50–100 anterior and 50–100 posterior tubules). For each individual, 
cysts which were found in the two anterior and two posterior tubules were scored and charted as 
nested plots using the Prism 8.0 (Graphpad) software (Figures 2.3-2.6). Vehicle-treated 
Drosophila presented several cysts in both the anterior and posterior Malpighian tubules, 
especially in the terminal and intermediate regions, and fewer cysts in the proximal region, as 
reported previously (58). Similar to PKD patients (1), a variable number of cysts was found in 
different individuals (58). In general, Smac-mimics appeared to reduce tubular cysts in both 
BicC allelic combinations (Tables 2.1 and 2.2).   
Effects of Smac mimic administration were recorded as overall cyst reduction (Tables 2.1 
and 2.2). Nested plots were used to represent individual variability in cyst number in the 
analyzed populations. Administration of peptide 1 to BicC!/YC33 Drosophila (n = 50) reduced 
cystic deformities respectively by 44% and 20% (228 vs. 127 cysts and 276 vs. 220 cysts, p = 
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0.0005 and 0.0457) in the anterior and posterior tubules, respectively (Table 2.1, Figure 2.3A,B). 
Administration of mimic 2 to BicC!/YC33 mutants (n = 50) reduced tubular cysts by 24% and 34% 
(216 vs. 165 cysts, p = 0.0324 and 244 vs. 162 cysts, p = 0.0017) in the anterior and posterior 
tubules, respectively (Table 2.1, Figure 2.3A,B). Administration of mimic 3 to BicC!/YC33 Drosophila 
(n = 50) reduced cysts in the anterior and posterior tubules respectively by 21% and 34% (195 vs. 
153 cysts, p = 0.1028 and 238 vs. 156 cysts, p = 0.0014, Table 2.1, Figure 2.3A,B). Finally, 
administration of mimic 4 to BicC!/YC33 mutants (n = 50) reduced cysts in the anterior and posterior 
tubules respectively by 31% and 18% (134 vs. 93 cysts, p = 0.0553 and 152 vs. 124 cysts, p = 
0.1877, Table 2.1, Figure 2.3A,B). 
 
Table 2.1 Overall cyst reduction upon Smac-mimic treatment of BicC!/YC33 Drosophila. 
 Anterior Tubule Posterior Tubule 










Reduction p value 
1 228 127 44% 0.0005 276 220 20% 0.0457 
2 216 165 24% 0.0324 244 162 34% 0.0017 
3 195 153 21% 0.1028 238 156 34% 0.0014 
4 134 93 31% 0.0553 152 124 18% 0.1877 
 





Figure 2.3 Smac mimics reduced cysts in BicC!/YC33 Drosophila. (A). Representative Malpighian 
tubules micro-dissected from BicC!/YC33 Drosophila treated with either vehicle or analogs 1, 2, 3, 
and 4 (indicated) were photographed ex vivo. Arrows indicate cysts. In each image, anterior pairs are 
at the top, posterior pairs at the bottom. Scale bar: 1 mm. (B). Nested plots depicting number of cysts 
found in the anterior and posterior tubule pairs of vehicle- and Smac mimic-treated cystic 
Drosophila (indicated), with mean and standard deviation. P values (with Welch’s correction) are 
indicated. Treatments are indicated with color: vehicle, grey; mimic 1, sepia; 2, blue; 3, dark pink; 4, 
brown.  
The analogs were next administered to the BicC!/IIF34 Drosophila carrying the allelic 
combination which produced a more severe phenotype. Treatment with peptide 1 decreased 
cystic deformations respectively by 44% and 37% (total 357 vs. 199 cysts and 433 vs. 272 cysts, 
p < 0.0001 and 0.0002, respectively) in the anterior and posterior tubules of the micro-dissected 
BicC!/IIF34 mutants (n = 50, Table 2.2, Figure 2.4A,B). Administration of mimic 2 to BicC!/IIF34 
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Drosophila (n = 50) reduced cystic deformations by 39% in the anterior (233 vs. 142 cysts, p = 
0.0011) and by 33% in the posterior (302 vs. 202 cysts, p = 0.0020) tubules (Table 2.2, Figure 
2.4A,B). Administration of mimic 3 to BicC!/IIF34 mutants (n = 25) had a milder and highly 
variable effect on the renal tubules and reduced cystic deformities by 11% (114 vs. 102 cysts, p = 
0.6317) and 21% (155 vs. 122 cysts, p = 0.2285) in the anterior and posterior tubules 
respectively (Table 2.2, Figure 2.4A,B), below statistical relevance thresholds. Finally, 
administration of mimic 4 to BicC!/IIF34 Drosophila (n = 50) reduced cysts in the anterior and 
posterior tubules by 40% (199 vs. 119 cysts, p = 0.0005) and 38% (243 vs. 151 cysts, p = 
0.0002) respectively (Table 2.2, Figure 2.4A,B). Parallel respective administration of analogs 1–
4 to control, non-cystic OreR wild type individuals did not change Malpighian tubule 
morphology. 
 
Table 2.2 Overall cyst reduction upon Smac-mimic treatment of BicC!/IIF34 Drosophila 
 Anterior Tubule Posterior Tubule 










Reduction p value 
1 357 199 44% < 0.0001 433 272 37% 0.0002 
2 233 142 39% 0.0011 302 202 33% 0.0020 
3 114 102 11% 0.6317 155 122 21% 0.2285 
4 199 119 40% 0.0005 243 151 38% 0.0002 
 





Figure 2.4 Smac mimics reduced cysts in BicC!/IIF34 Drosophila. (A). Representative Malpighian 
tubules micro-dissected from BicC!/IIF34 Drosophila treated with either vehicle or analogs 1, 2, 3, 
and 4 (indicated) were photographed ex vivo. Arrows indicate cysts. In each image, anterior pairs are 
at the top, posterior pairs at the bottom. Scale bar: 1 mm. (B). Nested plots depicting number of cysts 
found in the anterior and posterior tubule pairs of vehicle- and Smac mimic-treated cystic Drosophila 
(indicated), with mean and standard deviation. P values (with Welch’s correction) are indicated. 
Treatments are indicated with color: vehicle, grey; mimic 1, sepia; 2, blue; 3, dark pink; 4, brown.  
 
Distinct Malpighian tubule regions in both the anterior and posterior tubules appeared to 
respond differentially to the Smac mimics. The cyst location was thus specifically mapped in the 
proximal, intermediate and terminal regions of the anterior and posterior tubules respectively 
(Tables 2.3 and 2.4), and individual variable cyst numbers similarly plotted (Figures 2.5 and 2.6). 
Absolute numbers for the cysts in each region described below are listed in Table S2. 
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2.3.2.1. Smac Mimics Differentially Affect Distinct Regions of the Malpighian Tubules. 
Administration of peptide 1 to the milder allelic combination BicC!/YC33 (n = 50) reduced cysts in 
the terminal and intermediate regions of the anterior tubules respectively by 53% and 34% (total 
122 vs. 57, 104 vs. 69 cysts, p < 0.0001 and p = 0.0381, Table 2.3, Figure 2.5A). In the proximal 
region of the anterior tubules, two cysts were found in the control versus one cyst in the treated 
samples, precluding statistical analyses. In the posterior tubules, administration of peptide 1 
diminished cysts in the intermediate region by 26% (total 109 vs. 80 cysts, p = 0.0449). In the 
terminal and proximal regions, a trend toward decreased cysts was observed, albeit without 
reaching a statistical threshold for significance (respectively 108 vs. 84 cysts, 22% reduction, p = 
0.1405, and 59 vs. 56 cysts, 5% reduction, p = 0.7531, Table 2.3, Figure 2.5A). 
 
Table 2.3 Percentage of cyst reduction upon treatment of BicC!/YC33 Drosophila. 
Smac-mimic Anterior tubule Posterior tubule Prox. Int. Term. Prox. Int. Term. 
1 (n = 50) n/s 
34% 
p = 0.0381  
53% 
p < 0.0001 
5% 
p = 0.7531  
26% 
p = 0.0449  
22% 
p = 0.1405  
2 (n = 50) n/s  
5%  
p = 0.7599 
41% 
p = 0.0006  
47% 
p = 0.0057  
29% 
p = 0.0389 
32% 
p = 0.0125  
3 (n = 50) n/a  
2% 
p = 0.9072 
40% 
p = 0.0041 
21% 
p = 0.2431 
30% 
p = 0.0465 
45% 
p = 0.0007 
4 (n = 50) n/a 
36% 
p = 0.0461 
20% 
p = 0.3377 
n/s 
p = 0.4769 
33% 
p = 0.0130 
n/s 
p = 0.9245 





Figure 2.5 Smac mimics reduce cysts in BicC!/YC33 Drosophila with varying regional 
specificity. Malpighian tubules from 50 BicC!/YC33 Drosophila were micro-dissected after 20 
days of treatment (age 27-29 days). Cysts were scored ex vivo. For each individual, cysts 
numbers were recorded for the terminal, intermediate and proximal region of the Malpighian 
tubules, independently for the anterior (left) and posterior (right) tubules. Drosophila were 
administered either vehicle (water, grey) or Smac mimics 1 (A, sepia), 2 (B, blue), 3 (C, dark 
pink), and 4 (D, brown). Mean and standard deviation are indicated. Analogs 1 and 2 best 
reduced tubular cysts, mimic 3 was effective at reducing cysts in the terminal region of the 
anterior tubules and mimic 4 had a mild effect in the intermediate region of both tubule pairs. P 
values (with Welch’s correction) are indicated. BicC!/YC33 Drosophila exhibit the milder cystic 
defects.  
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Administration of peptide 1 to BicC!/IIF34 Drosophila reduced cysts in the anterior tubules 
by 40% and 48% (total 156 vs. 94 and 193 vs 100 cysts, p = 0.0038 and p < 0.0001) in the 
terminal and intermediate regions, respectively (Table 2.4, Figure 2.6A). In the proximal region 
of the anterior tubules, a trend of cyst reduction was observed, albeit fewer cysts (eight and five 
in vehicle- and peptide 1-treated tubules) and high individual variability precluded a margin of 
confidence. In the posterior tubules, administration of peptide 1 reduced cysts in the terminal, 
intermediate and proximal regions by 32%, 41% and 39% (total 180 vs. 122, 167 vs. 98, 86 vs. 
52 cysts, p = 0.0022, 0.0008 and 0.0150), respectively (Table 2.4, Figure 2.6A). 
 
Table 2.4 Percentage of cyst reduction upon treatment of BicC!/IIF34 Drosophila. 
Smac-
mimic 
Anterior tubule Posterior tubule 
Prox. Int. Term. Prox. Int. Term. 
1 (n = 50) n/s 
48% 
p < 0.0001  
40% 
p = 0.0038  
39% 
p = 0.0150  
41% 
p = 0.0008  
32% 
p = 0.0022  
2 (n = 50) n/a 
41% 
p = 0.0045  
37% 
p = 0.0161  
43% 
p = 0.0080  
27% 
p = 0.0703  
32% 
p = 0.0086  
3 (n = 25) n/a 
9% 
p = 0.7140  
11% 
p = 0.6746 
40% 
p = 0.1325  
10% 
p = 0.7038  
21% 
p = 0.2429  
4 (n = 50) n/s 
42% 
p = 0.0014  
38% 
p = 0.0195  
35% 
p = 0.1069  
22% 
p = 0.1231  
51% 
p < 0.0001  





Figure 2.6 Smac mimics reduce cysts in BicC!/IIF34 Drosophila with varying regional 
specificity. Malpighian tubules from 50 BicC!/IIF34 Drosophila were micro-dissected after 20 
days of treatment (age 27-29 days). Cysts were scored ex vivo. For each individual, cysts 
numbers were recorded for the terminal, intermediate and proximal region of the Malpighian 
tubules, independently for the anterior (left) and posterior (right) tubules. Drosophila were 
administered either vehicle (water, grey) or Smac mimics 1 (A, sepia), 2 (B, blue), 3 (C, dark 
pink), and 4 (D, brown). Mean and standard deviation are indicated. Peptide 1 was the most 
effective at reducing cysts in the treated tubules. Mimics 2 and 4 showed great improvements in 
all regions except for the intermediate region of the posterior tubules and mimic 3 showed a very 
mild to no effect in cyst reduction. P values (with Welch’s correction) are indicated. BicC!/IIF34 
Drosophila exhibit the more severe cystic defects. 
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 Treatment with mimic 2 diminished cysts in the terminal region of the anterior tubules of 
BicC!/YC33 Drosophila (n = 50) by 41% (114 vs. 67 cysts, p = 0.0006). In the intermediate region, 
a mild 5% reduction was observed that did not approach a statistical significance threshold (102 
vs. 97 cysts, p = 0.7599, Table 2.3, Figure 2.5B). Precluding statistical analyses, no (control) and 
one cyst (mimic 2-treated) were detected in the proximal region of the anterior tubules. In 
contrast, in the posterior tubule, administration of mimic 2 reduced cysts in the terminal, 
intermediate and proximal regions by 32%, 29% and 47% (101 vs. 69 cysts, p = 0.0125, 96 vs. 
68 cysts, p = 0.0389 and 47 vs. 25 cysts, p = 0.0057), respectively (Table 2.3, Figure 2.5B). 
Administration of mimic 2 to the more severely cystic BicC!/IIF34 mutants (n = 50) reduced 
cysts in the terminal and intermediate regions of the anterior tubules by 37% and 41% (average 
115 vs. 72 cysts, p = 0.0161, 118 vs. 70 cysts, p = 0.0045), respectively. No cysts were found in 
the proximal regions of control and treated tubules (Table 2.4, Figure 2.6B). Administration of 
mimic 2 reduced cysts in the terminal and proximal regions of the posterior tubules by 32% and 
43% (134 vs. 91 cysts, p = 0.0086 and 69 vs. 39 cysts, p = 0.0080), respectively. The 
intermediate region displayed a 27% reduction that approached statistical significance threshold 
(99 vs. 72 cysts, p = 0.0703, Table 2.4, Figure 2.6B). 
After treatment with mimic 3, the BicC!/YC33 Drosophila (n = 50) harbored 40% fewer cysts 
in the terminal region of the anterior tubules (99 vs. 59 cysts, p = 0.0041). In the intermediate 
region, the effect was negligible (2% reduction, 96 vs. 94 cysts, p = 0.9072). No cysts were 
detected in the proximal region of both control and treated tubules (Table 2.3, Figure 2.5C). On 
the contrary, administration of mimic 3 reduced strongly cysts in the terminal and intermediate 
regions of the posterior tubules by 45% and 30% (100 vs. 55 cysts, p = 0.0007 and 90 vs. 63 
cysts, p = 0.0465), respectively. The proximal region displayed a trend towards cyst reduction 
with high individual variability (21% reduction, 48 vs. 38 cysts, p = 0.2431, Table 2.3, Figure 
2.5C). 
Mimic 3 did not ameliorate the more severely cystic BicC!/IIF34 mutants (n = 25). After 
treatment with mimic 3, the BicC!/IIF34 mutants displayed respectively 11% and 9% (61 vs. 54 
cysts, p = 0.6746 and 53 vs. 48 cysts, p = 0.7140) fewer cysts in the terminal and intermediate 
regions of the anterior tubules; no cysts were observed in the proximal region of both control and 
treated tubules (Table 2.4, Figure 2.6C). Similarly, mimic 3 caused respectively 21%, 10% and 
40% (75 vs. 59 cysts, p = 0.2429, 50 vs. 45 cysts, p = 0.7038 and 30 vs. 18 cysts, p = 0.1325) 
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reductions in cysts in the terminal, intermediate and proximal regions of the posterior tubules 
(Table 2.4, Figure 2.6C). 
Mimic 4 reduced cysts in the intermediate region of the anterior tubules of BicC!/YC33 
Drosophila (n = 50) by 36% (85 vs. 55 cysts, p = 0.0461). In the terminal region, a 20% decrease 
was observed, that did not reach a threshold of statistical significance (49 vs. 39 cysts, p = 
0.3377). No cysts were detected in the proximal region of both control and treated tubules (Table 
2.3, Figure 2.5D). Treatment with mimic 4 reduced cysts in the intermediate region of the 
posterior tubules by 33% (98 vs. 66 cysts, p = 0.0130), but did not reduce cysts in the terminal 
and proximal regions (Table 2.3, Figure 2.5D). 
Upon treatment with mimic 4, cysts were lessened in the terminal and intermediate regions 
of the anterior tubules of BicC!/IIF34 Drosophila (n = 50) by 38% and 42% (92 vs. 57 cysts, p = 
0.0195 and 106 vs. 62 cysts, p = 0.0014), respectively (Table 2.4, Figure 2.6D). Precluding 
statistical analysis, only one cyst was detected in the proximal region of control tubules and no 
cysts in the treated tubules. Administration of mimic 4 reduced cysts in the terminal region of the 
posterior tubules by 51% (113 vs. 55 cysts, p < 0.0001). Less cysts were also scored in the 
intermediate and proximal regions, although values did not reach the significance threshold 
(respectively 22% reduction, 90 vs. 70 cysts, p = 0.1231, and 35% reduction, 40 vs. 26 cysts, p = 
0.1069, Table 2.4, Figure 2.6D). 
Ineffective cyst reduction could be partly due to Drosophila refusing to ingest the Smac 
mimics. To assess their ingestion, the analogs were mixed with food and dye, and fed to mutants 
for four days. The green dye could be seen through the semi-transparent abdominal cuticle for all 
mimics, confirming analog ingestion (Figure S2.1). As a measure of hydrophilicity, the clogP 
values were calculated for the different Smac mimics (Figure 2.1) and found to be sufficiently 
low to be consistent with absorption: 1 (0.7), 2 (3.9), 3 (5.0), 4 (5.4). Together these results 
support the conclusion that the Smac analogs may have differential activities and/or processing. 
 
2.4 Discussion 
 A systematic analysis of the influences of the Smac mimic H-Ala-Val-Pro-Ile-NH2 (1) 
and constrained analogs 2–4 on renal cystogenesis has been performed using the novel BicC 
Drosophila model to recapitulate features of PKD (58). Two allelic combinations for BicC were 
used that yield cystic phenotypes of different severity, namely BicC!/YC33 and BicC!/IIF34. 
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Previously, the Smac mimic GT13072 reduced cystogenesis in a rat ADPKD model (46). In the 
BicC Drosophila, Smac mimics 1–4 ameliorated similarly the cystic condition with the strongest 
effects displayed in the more severely affected BicC!/IIF34 genotype. Peptide 1 exhibited the 
highest overall efficacy reducing cyst occurrence by 20–44% across genotypes at the anterior 
and posterior tubules. Moreover, aza-methanopipecolate 2 caused a 24–39% reduction of cysts. 
Aza-cyclohexylglycine 3 displayed least efficacy, but still improved significantly the posterior 
tubules of the BicC!/YC33 mutants. The related N-methyl-alaninyl-aza-cyclohexylglycine analog 4 
exhibited differential activity in the two BicC mutants, reducing cysts by ~40% in both tubules of 
the BicC!/IIF34 mutants. In contrast, analog 4 only showed a trend towards reducing cysts in the 
anterior tubule of the BicC!/YC33 Drosophila close to the significance threshold (p = 0.0553). The 
Smac mimics tested appeared to differentially affect the anterior and posterior tubule pairs 
overall, consistent with the report of the latter having distinct transcriptomes (70) and thus 
different physiological specialization. Mimics 1, 2 and 3 were found to induce death of 20% (1, 
2) and 60% (3) of cultured MCF7 adenocarcinoma cells (65). Their efficacy in other PKD 
models and patients is unknown. Smac mimics function in context-dependent ways, likely 
through different IAPs to affect apoptosis via several mechanisms (72). Due to its methyl group, 
N-methyl-alaninyl-aza-cyclohexylglycine analog 4 was expected to be more stable than aza-
cyclohexylglycine 3 in vivo (111-113), which was consistent with the observed higher cyst-
reducing activity. 
The tubular sections responded differentially to treatment with the Smac mimics. The 
terminal region consistently exhibited greater improvement, especially in the weaker BicC!/YC33 
allelic combination. Drosophila were shown to ingest the Smac mimics. The clogP values of 
mimics 1–4 were also within the range consistent with effective absorption. The distinct 
pharmacological responses observed at different regions of the Malpighian tubules may be 
related to variability in absorption, metabolism and response to Smac mimics within cystic cells 
in such regions. Regional specialization of Malpighian tubules has been observed despite the 
tubular epithelium being composed by only two major cell types (reviewed in (57), (114)). 
Cystogenesis may perturb cells and reduce the threshold for initiating cell death pathways either 
through caspase-dependent apoptosis or the TNF signaling pathway. The contribution of 
apoptosis to the early phases of ADPKD is a matter of debate (115); however, the TNF pathway 
has been implicated in ADPKD-type renal cystogenesis and suggested to be the primary target of 
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Smac mimics in a rat model of Pkd1-dependent ADPKD (46). The results presented here predict 
that the BicC mutation may feature dysregulated TNF signaling in the epithelial cells of the 
Malpighian tubules, as observed in ADPKD-type cystogenesis. The expression of TNF (Eiger) 
and TNF pathway components in the Malpighian tubules and their respective contributions to 
tubular function are however unknown. The human BicC orthologue BICC1 has been found to be 
genetically downstream of the main PKD1 gene (58). The pharmacological response to Smac 
mimics was herein demonstrated to be conserved in Drosophila illustrating further the 
phenotypic and molecular similarities between PKD1-induced and BicC-induced renal 
cystogenesis. 
Notably, pharmacological binding sites have been found to be conserved in Drosophila 
(116). Chemical probing in Drosophila in vivo may thus rapidly pinpoint the involvement of 
specific pathways with complementarity to genetic analyses, indicate conserved biological 
activity of drug-prototypes, and provide a rapid read-out for effectiveness of pharmacological 
modulation of specific pathways involved in cystic pathogenesis. The Smac mimics affected 
different tubular regions differentially. Considering that such specificity may be conserved to 
humans, the development of personalized pharmacological treatments for cystic renal diseases 
















2.5 Supplementary Materials to Chapter 2 
 
 
Figure S2.1 Analog feeding control. BicC mutants fed Smac mimics mixed with green dye for 
four days, displayed ingested food contents visible through their semi-transparent abdominal 














Chapter 3: General conclusions and future directions 
 
My thesis consists of a primary research article published in 2019 and also a review 
published in 2018, which is included in Appendix II. I have discussed how Drosophila can be 
valuable to model human renal cystic diseases due to remarkable conservation of genes, 
pathways and morphological features. Of specific advantage to the study of diseases causing the 
formation of cysts of the renal tubule such as PKD, anatomically separated Malpighian tubules 
enable detailed phenotypic analyses such as the ones shown in this thesis. Particularly suitable to 
drug discovery, the small size of Drosophila also facilitates drug-screening in vivo using 
analytical amounts of compounds. Mutations in the human BICC1, murine Bicc1 and other BicC 
vertebrate orthologs all cause the formation of renal cysts. We have shown that in PKD mutation 
of the human PKD1 and murine Pkd1 genes cause reduced function respectively of the BICC1 
and Bicc1 orthologs (58). Together with the observation that BicC loss of function is sufficient to 
induce renal cysts, this suggests that BicC is a contributor to renal cystic pathogenesis in human 
PKD1 and murine Pkd1 mutants. Thus, characterization of the effects of BicC loss of function 
may help unravel the complex events of renal cyst formation.  
BicC mutation in Drosophila produces a phenotype reminiscent of PKD, characterized by 
a degenerative trajectory. In Drosophila BicC mutants, cysts form along all regions of the 
Malpighian tubules, with highest frequency in the terminal and intermediate regions. The BicC 
Drosophila model also displays several molecular markers of PKD, including Myc and mTOR 
up-regulation (58). Therefore, the BicC Drosophila model can be leveraged to study conserved 
aspects of the complex processes of renal cysts. This thesis shows a first proof-of-principle 
application of such model for drug discovery. 
Because multiple pathways promoting cell proliferation are dysregulated in PKD, 
including c-Myc and mTOR, several anti-cancer drugs have been and are being tested to reduce 
cysts in PKD. Among these, Smac mimetics neutralize IAPs leading to activation of caspases 
and apoptosis (75). In ADPKD, TNF-α accumulates in the cystic fluid, which offers opportunity 
to target preferentially cystic cells and not neighbouring renal epithelial cells (46). The role of 
TNF signaling in Malpighian tubules is unknown, however, TNF, its receptor and downstream 
factors are conserved in Drosophila, although their functions need to be explored. Additionally, 
Reaper, Hid and Grim proteins (which are all Drosophila IAP antagonists similar to Smac) could 
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induce apoptosis when transfected in mammalian cells (53). Such extensive conservation 
suggested that Smac mimicry may function in the cystic Drosophila model, should TNF be dys-
regulated in the BicC mutant, similar to PKD.  
Overall, Smac mimics 1-4 all reduced cystogenesis of the BicC!/YC33 and BicC!/IIF34 
Drosophila. Smac mimic 1 was the most efficient reducing cysts overall by 44% for both allelic 
combinations, followed by mimic 2 (34 and 39%, respectively), and 4 (31 and 40%, 
respectively). As well, distinct regions of the Malpighian tubules showed differential 
improvements to Smac mimic treatment, highlighting functional differences along the tubule that 
will be further characterized in future. The cystic index scored here is qualitative, because it 
exclusively tallied cysts and did not include other parameters that may be consequential, such as 
cyst size and morphology. How these may influence the cysts and the cystic portions of the 
epithelium (compared to the non-cystic surroundings) is unknown in both PKD and in the 
recently-established Drosophila PKD model. Cyst size, especially in the context of the vertebrate 
kidney where nephrons are embedded in parenchymal tissue, is expected to impact both 
mechanical deformation and, likely, the induction of stress-induced apoptosis of the surrounding 
tissues (11). In fact, in PKD only 1% of the nephrons are cystic, yet the kidneys are eventually 
damaged completely and irreparably (e.g., see Figure 1.1).  Therefore, slowing cyst enlargement 
is also expected to delay kidney damage and prolong the time before dialysis and transplant are 
needed. The way I counted cysts may be considered particularly stringent because of the lack of 
accounting of cystic size. However, cyst size and morphology are largely uncharacterized, and 
their appropriate quantification is a matter of debate in the field of PKD studies. Because of the 
likely relevance of these parameters and the accessibility of the Drosophila Malpighian tubules 
facilitating direct examination, our laboratory is developing tools to measure such parameters as 
we tease apart the underlying biology of renal cyst formation using the streamlined Drosophila 
model. In future studies, these tools, together with increased knowledge of how Smac mimicry 
affects the complex mechanisms of cyst formation, may reveal that the numerical cyst reduction 
observed from Smac mimic treatment may indeed be accompanied by a higher overall rescue of 
the cystic phenotype. 
The observation that Smac mimics could reduce cysts in the Drosophila PKD model 
without the addition of exogenous TNF, also suggests that TNF and its receptor may be up-
regulated in the BicC Drosophila Malpighian tubules, a possibility consistent with preliminary 
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data from our ongoing research. If confirmed, this finding would further extend the similarities 
between human PKD and the cystic Drosophila model and add a novel aspect to the complex 
BicC mutant phenotype. In perspective, using this model appears a valid first step to characterize 
the conserved molecular pathways involved in renal cystic growth, including cell proliferation, 
apoptosis, cell-cell contacts and the associated molecular markers, including proliferation 
factors, cell junction proteins, signal transduction and TNF pathway components. The BicC 
Drosophila model will likely help to elucidate the functions of the TNF pathway in Drosophila 
Malpighian tubules and decipher the mechanism of action for Smac mimics in Drosophila. 
Albeit cyst reduction in vertebrates is expected to retard loss of kidney function, it is unclear if 
Smac mimics can also rescue polarization of the tubular epithelium and the filtration function of 
the renal tubules. These fundamental aspects can be efficiently studied in isolated Drosophila 
Malpighian tubules in which epithelial and other cell markers can be monitored by immunoblots 
and immunostaining. Moreover, individual tubule filtration indicative of physiological function, 
can be measured by Drosophila Ramsay assays (117) and can be used to compare fluid secretion 
from Malpighian tubules of vehicle and Smac-mimic-treated Drosophila.  
To fully confirm efficacy and drug potential for Smac mimicry in PKD, these studies will 
have to be extended to vertebrate models and, eventually, clinical trials. Because of the influence 
of cellular context on TNF upregulation levels and signaling, Smac mimic response in patients 
may ultimately vary depending on factors such as the individual PKD1 mutations and the 
random variable of which tubular region(s) may have developed most cysts. Optimal 
administration to effectively reach and improve the cystic tubules embedded in the (vertebrate) 
kidney, long-term efficacy and safety will also have to be determined.  
 One interesting observation is that in both the murine and Drosophila cystic models, 
Smac mimics appeared to reduce, yet not completely eliminate cysts (46,64). Smac mimics are 
considered combination drugs in oncology(43) and may similarly be more effective when used 
jointly to other compounds in PKD. However, lacking a cure for renal cystic diseases such as 
PKD, a safe way of inducing cyst reduction is considered a milestone because it would delay the 
need for costly procedures such as dialysis and transplant and lead to a better quality of life for 
the patients, as kidney enlargement cause severe  abdominal pain from compression  and painful 
events of cyst rupture that may lead to secondary infections. 
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While the biological underpinning of renal cyst formation is complex and there is a lot 
more to investigate about its molecular pathways, our research begins to offer some clues as to 
the conserved molecular players in the cystic process. One of such players with implications on 
our understanding of PKD pathology appears to be BicC. My research presented here, 
demonstrated feasibility of discovering drug candidates displaying cyst-reducing activity in vivo 
using the BicC Drosophila model of PKD. Further drug development potential will be evaluated 
for such identified molecules. The drug-testing protocols presented here can be scaled up for 
increased throughput and testing other compounds and libraries that can be combined with the 
genetic approaches well established in Drosophila. Intriguingly, this research has also provided 
clues to novel BicC functions in the Malpighian tubule as a potential TNF modulator, either 
direct or indirect. Thus, chemical testing in Drosophila may also benefit efforts to tease apart the 
conserved, fundamental molecular underpinning of BicC mutation-dependent renal cyst 
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Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited malady aecting
12.5 million people worldwide. Therapeutic options to treat PKD are limited, due in part
to lack of precise knowledge of underlying pathological mechanisms. Mimics of the second
mitochondria-derived activator of caspases (Smac) have exhibited activity as antineoplastic agents
and reported recently to ameliorate cysts in a murine ADPKD model, possibly by dierentially
targeting cystic cells and sparing the surrounding tissue. A first-in-kind Drosophila PKD model has
now been employed to probe further the activity of novel Smac mimics. Substantial reduction of cystic
defects was observed in the Malpighian (renal) tubules of treated flies, underscoring mechanistic
conservation of the cystic pathways and potential for ecient testing of drug prototypes in this
PKD model. Moreover, the observed dierential rescue of the anterior and posterior tubules overall,
and within their physiologically diverse intermediate and terminal regions implied a nuanced response
in distinct tubular regions contingent upon the structure of the Smac mimic. Knowledge gained
from studying Smac mimics reveals the capacity for the Drosophila model to precisely probe PKD
pharmacology highlighting the value for such critical evaluation of factors implicated in renal function
and pathology.
Keywords: renal cystogenesis; Drosophila; disease models; Smac mimicry; polycystic kidney
disease; azapeptide
1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD) induces the formation of cysts along
the entire renal tubule, predominantly at the terminal region and the collector tubule, as well as
extra-renal manifestations [1]. Inherited through a monogenic pattern with the most frequent mutations
aecting the PKD1 or PKD2 gene, ADPKD displays high heterogeneity in both phenotype and speed of
progression [1]. Abnormal proliferation of the epithelial tubular cells during development gives rise to
cysts prenatally. Cysts become more numerous with age, gradually enlarging and filling with fluid [1].
Animal models of PKD have been invaluable for defining disease progression and identifying key
molecular alterations; however, the precise mechanisms underlying disease pathology remain to be
elucidated at the molecular level [2]. The most recent addition to the arsenal of PKD animal models has
been the fruit fly, Drosophila melanogaster. Mutants for the Bicaudal C (BicC) gene (hereby BicC flies) were
found to recapitulate key molecular features of PKD, including myc over-expression and mechanistic
target of rapamycin (mTOR) pathway activation [3]. Consistent with ADPKD, the BicC flies formed
cysts along the entire length of the tubule, with higher frequency at the intermediate, terminal and
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collector tubule regions [3]. Moreover, analogous to vertebrate PKD [4–8], pharmacological treatment
of BicC flies with rapamycin transiently reduced cysts [3]. Consistent with the relevance of the BicC
phenotype in PKD, BICC1 mRNA and Bicc1 protein orthologues were respectively found to decrease in
kidneys from PKD1 patients and Pkd1-/- mice [3]. Thus, PKD1 dysfunction is associated with decreased
BicC function.
An excellent model of human renal function, the fly has high genetic conservation and a streamlined
anatomy (reviewed in [9]). In contrast to the human kidney, which contains one million tubular filtering
units called nephrons, Drosophila harbors two pairs of Malpighian tubules (MTs), which are functionally
equivalent to the tubular portion of the nephron. Suitable to the open circulatory system of the fly,
the renal system does not have glomeruli and possesses nephrocytes, which exhibit re-adsorptive
function analogous to the human glomerular podocytes [9]. Originating from the interface between
the mid- and hind-gut, the MTs are asymmetrical with longer tubules anteriorly and shorter ones
posteriorly. Reminiscent of the dierent nephron types in the human kidney, the anterior and posterior
MTs have distinct transcriptomes [10]. Like the human renal tubules, MTs can be divided into distinct
regions, which in the fly are called proximal, intermediate, and terminal. The proximal region excretes
fluid into the tubules, the intermediate region secretes potassium chloride and water, and the terminal
region is responsible for sodium and, possibly, water reabsorption [9]. One key advantage of the fly
renal system is that the MTs are anatomically distinct, float freely in the fly body cavity, and can be
cleanly micro-dissected and examined in their entirety.
Antineoplastic mimics of the second mitochondria-derived activator of caspases (Smac, also called
the direct inhibitor of apoptosis-binding protein with low pI, DIABLO) have been used to sensitize
cancer cells to apoptosis by targeting inhibitors of apoptosis proteins (IAPs, [11,12]). Highly conserved,
IAP proteins play a key role in balancing cell survival and cell death through multiple intersecting
cellular pathways. Implicated in innate immunity [13,14], IAPs are often upregulated in cancer [15].
First discovered in insect baculovirus as inhibitors of cellular apoptosis which enable viral replication,
IAPs were found in both vertebrates and invertebrates [16] (reviewed in [11]). The best-known
mammalian IAPs are X-linked IAP (XIAP), cellular IAP1 (cIAP1) and cIAP2 [11]. The Drosophila
genome encodes four IAPs, Diap1, Diap2, dBruce and Deterin [17–19]. Multiple proteins have been
shown to antagonize IAPs. First discovered in Drosophila, three proteins, Reaper [20], Head involution
defective (Hid, [21]) and Grim [22], can induce apoptosis when transfected into mammalian cells,
which demonstrated functional conservation of the apoptotic cellular machinery [23]. Additional fly
IAP antagonists are Jafrac [24], Sickle [25–27] and HtrA2 [28–30]. The search for the mammalian IAP
antagonists yielded Smac/DIABLO [31,32], Omi/HtrA2 [33], apoptosis-related protein in the TGF
signaling pathway (ARTS, [34]) and XIAP-associated factor 1 (XAF1, [35]). IAP antagonists function
through an RHG motif, named after the prototypical Reaper, Hid and Grim fly proteins. In the
case of the well-studied human Smac/DIABLO and fly Hid IAP antagonists, pro-apoptotic stimuli
induce proteolytic cleavage exposing the RHG motif at the N-terminus enabling interaction with IAP
proteins [36,37] and triggering their ubiquitination and degradation. In the appropriate cellular context,
IAP degradation can eventually lead to cell death either by way of caspase activation or via tumor
necrosis factor (TNF) signaling [11,38,39]. The discovery that the Smac/DIABLO N-terminal peptide
H-Ala-Val-Pro-Ile-NH2 can recapitulate the pro-apoptotic function of the entire protein has inspired the
development of various Smac mimics, which enable sensitization of neoplastic cells to apoptosis [12].
Based on the premise that ADPKD is considered in part a neoplastic condition [40,41], and that
various TNF complex components were upregulated in Pkd1-/- mouse embryonic kidney (MEK) cells,
the Smac mimic and birinapant analog GT13072 was used to induce TNF--dependent cell death in
both cultured cells and a rat model of PKD [42]. The pro-apoptotic properties of GT13072 were specific
for the TNF-positive renal epithelial cystic cells and spared surrounding non-cystic cells, oering
therapeutic potential to ablate renal cystic cells to delay cystogenesis [42].
The TNF pathway is highly conserved in the fly [43–48]. The capacity for Smac mimics to reduce
MT cystogenesis has now been tested in the BicC cystic flies. The prototypical H-Ala-Val-Pro-Ile-NH2
Biomedicines 2019, 7, 82 3 of 17
(peptide 1, Figure 1) and three Smac mimics 2–4 were administered to the BicC cystic flies to reduce
cyst formation.
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Figure 1. Second mitochondria-derived activator of caspases (Smac) analogs: peptide 1 and mimics 2–4 
(Val, aza-residue and modified N-terminal in blue). Logarithm of the partition coefficient (clogP) 
values were calculated as described below. 
2. Experimental Section 
2.1. Fly Lines and Genetics 
Fly breeding and care were previously described in detail [3]. In brief, flies were grown on 
cornmeal agar (Jazzmix, Fisher Scientific Canada, Ottawa, ON) at 25 °C and aged as indicated. 
OregonR (OreR) wild-type flies were maintained as in [3]. BicC mutants were generated by crossing 
Df(2L)RA5/CyO (BicC-encompassing deletion obtained from Bloomington Drosophila Stock Center) 
virgin females with one of the two hypomorphic BicC mutations, BicCYC33/CyO and BicCIIF34/CyO and 
selecting straight-winged progeny (Df(2L)RA5/BicCYC33, BicCΔ/YC33 and Df(2L)RA5/BicCIIF34, BicCΔ/IIF34). 
The two BicC allelic combinations produced truncated proteins and sterile BicC flies [3]. Eclosed adult 
flies were collected every two days to yield 0–2-day old populations and aged as described. 
2.2. In Vivo and Ex Vivo Assays 
2.2.1. Cystic Index 
For the cyst analysis, 0–2-days old flies were aged seven days (i.e., 7–9 days old) and were fed 
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Figure 1. Second mitochondria-derived activator of caspases (Smac) analogs: peptide 1 and mimics
2–4 (Val, aza-residue and modified N-terminal in blue). Logarithm of the partition coecient (clogP)
values were calculated as described below.
2. Experimental Section
2.1. Fly Lines and Genetics
Fly breeding and care were previously described in detail [3]. In brief, flies were grown on
cornmeal agar (Jazzmix, Fisher Sci ntific Canada, Ottawa, ON) at 25 C and aged as indicated.
OregonR (OreR) wild-type flies were maintained as in [3]. BicC mutants were generated by crossing
Df(2L)RA5/CyO (BicC-encompassing deletion obtai ed from Bloomington Drosophila Stock Center)
virgin females with on of the two hypomorphic BicC mutations, BicCYC33/CyO and BicCIIF34/CyO and
selecting straight-winged progeny (Df(2L)RA5/BicCYC33, BicCD/YC33 andDf(2L)RA5/BicCIIF34, BicCD/IIF34).
Th two BicC allelic combinations produced truncated proteins and sterile BicC flies [3]. Eclosed adult
flies ere collected every two days t yield 0–2-day old populations and aged as described.
2.2. In Vivo and Ex Vivo Assays
2.2.1. Cystic Index
For the cyst analysis, 0–2-days old flies were aged seven days (i.e., 7–9 days old) and were fed
every three days with 2 mL of cornmeal food and equal volumes (50 L) of either vehicle (water) or an
aqueous solution containing peptide 1 or Smac mimic 2–4. Each compound was used at 20 M and
was administered for 20 days (i.e., until 27–29 days old). Malpighian tubules were micro-dissected
from 25–50 female flies in phosphate buered saline (PBS) and the number of cysts was scored
separately in anterior and posterior tubules and assigned to each tubular region (i.e., proximal,
intermediate and terminal [3,9]), as follows. At one extremity, the proximal region consists of about
15% of the tubule length, tends to have an opaque whitish content (posterior tubule), is thinner than
adjacent regions (especially in the anterior tubule) and often exhibits a slight constriction terminally.
The neighboring intermediate region has darker contents and consists of about 55% of the tubule length.
The terminal region is often translucent, directly connected to the collecting tubule, and consists of
the remaining 30% of the tubule length. Cysts were considered tubular deformations creating uni-
or bi-laterally protuberant pouches. Extra-branches (as in [3]) were counted as cysts. Values were
plotted using the Prism 8.0 software (Graphpad Software, San Diego, CA, USA) as nested distributions.
Statistical analyses were performed as unpaired t tests with Welch’s correction (the populations may
not have equal standard deviations). The raw data counts are listed in Supplementary Table S1.
2.2.2. Microscopy
Malpighian tubules from appropriately aged and treated flies were micro-dissected in 1 PBS,
equilibrated into a 3:1 1 PBS:glycerol solution and photographed on a Leica MZ FLIII Fluorescence
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Stereomicroscope with Leica MZ series 10/21B Widefield adjustable eyepieces equipped with a Canon
DS126201 EOS 5D MARK II camera, using visible light. Canon raw files (CR2) were converted into TIF
format using the Adobe Lightroom 3.2 software (Adobe Systems, San Jose, CA, USA).
2.3. General Synthetic Methods
Chemicals were used as received from commercial sources without further purification unless
stated otherwise. All glassware was stored in the oven or flame-dried and let cool under an inert
atmosphere prior to use. Anhydrous solvents (DCM, and DMF) were obtained by passage through
solvent filtration systems (Glass-Contour, Irvine, CA, USA). Silica gel chromatography was performed
using 230–400 mesh silica gel (Silicycle), and TLC was on glass-backed silica plates visualizing the
developed chromatogram by UV absorbance or staining with ceric ammonium molybdate or potassium
permanganate solutions. Nuclear magnetic resonance spectra (1H and 13C) were recorded on a
Bruker AV 500 spectrometer and referenced to residual solvent in CD3OD (3.31 ppm, 49.0 ppm).
Coupling constant J values and chemical shifts were measured in Hertz (Hz) and parts per million
(ppm). Infrared spectra were recorded in the neat on a Perkin Elmer Spectrum One FTIR instrument
and are reported in reciprocal centimeter (cm–1). Liquid chromatography mass spectrometry (LC MS)
was performed on an Agilent Technologies 1200 series instrument in positive electrospray ionization
(ESI)-time-of-flight (TOF) mode at the Université de Montréal Mass Spectrometry Facility. Sodium and
proton adducts ([M + Na]+ and [M + H]+) were used for empirical formula confirmation. The peptide
H-Ala-Val-Pro-Ile-NH2 (1), Smac mimics 2 and 3, and aza-cyclohexylglycinyl-l-proline benzhydrylamide
(8), all were synthesized according to published methods [49]. N-Boc-N-Methyl-l-alanine and diisopropyl
ethyl amine (DIEA) were purchased from Aldrich or Alfa Aesar and used without further purification.
Benzotriazol-1-yl-oxytripyrrolidino-phosphoniumhexafluoro-phosphate (PyBop) was purchased from GL
Biochem, recrystallized prior to use from dry CH2Cl2/Et2O (melting point, 156 C), and stored in the dark.
N-Methyl alaninyl-aza-cyclohexylglycinyl-l-proline benzhydrylamide (4). A solution of
aza-cyclohexylglycinyl-l-proline benzhydrylamide (8, 1 eq., 65 mg, 0.155 mmol, prepared
according to [49]) and DIEA (2 eq., 40 mg, 53 L, 0.309 mmol) was added to a solution of
N-(tert-butoxycarbonyl)-N-methyl-l-alanine (1.2 eq., 38 mg, 0.186 mmol) and PyBOP (1.5 eq., 121 mg,
0.233 mmol) in DMF (3 mL), and the mixture was stirred overnight. The volatiles were removed
under vacuum. The residue was dissolved in EtOAc (10 mL), washed with 5 mL of saturated aqueous
NaHCO3 and brine (10 mL), dried over Na2SO4, filtered, and evaporated. Without further purification,
the residue was dissolved in a 25% solution of trifluoroacetic acid in dichloromethane (2 mL) and
stirred for 2 h. The volatiles were removed under vacuum. The residue was dissolved in CH2Cl2
and the solution was evaporated. The residue was suspended in 2 mL of 1N HCl, stirred for 30 min,
and freeze-dried to give the hydrochloride salt as o white solid, which was purified by RP-HPLC on a
reverse-phase Gemini® C18 column (Phenomenex® Inc., pore size: 110 Å, particle size: 5 m, 250 
21.2 mm) using a binary solvent system consisting of a gradient of 5–60% MeOH [0.1% formic acid
(FA)] in water (0.1% FA) with a flow rate of 10.0 mL/min and UV detection at 214 nm. The desired
fractions were combined and freeze-dried to white fluy powder: azapeptide 4 (5.2 mg, 0.01 mmol,
7%): mp 93–94 C; 1H NMR (500 MHz, CD3OD)  8.40 (s, 1H), 7.45–7.20 (m, 10H), 6.24 (s, 1H), 4.56–4.42
(m, 1H), 4.05–3.88 (m, 1H), 3.69–3.42 (m, 2H), 2.59–2.43 (m, 3H), 2.43–2.31 (m, 1H), 2.26–2.14 (m, 1H),
2.14–2.00 (m, 1H), 2.00–1.91 (m, 1H), 1.91–1.62 (m, 6H), 1.53–1.36 (m, 5H), 1.35–1.03 (m, 5H); 13C NMR
(125 MHz, MeOD)  174.1, 171.2, 161.4, 143.2, 139.1, 129.5 (2C), 129.4 (2C), 129.3 (2C), 128.8 (2C), 128.4,
128.2, 63.6, 57.9, 57.4, 49.6, 31.5, 31.3, 30.8, 26.9, 26.72 (2C), 26.69 (2C), 26.5, 17.5; IR (neat) vmax/cm 1
2929, 1638, 1532, 1495, 1449, 1406, 1344, 1323, 1095; HRMS m/z calculated for C29H40N5O3 [M+H]+
506.3126; found 506.3139. (Supplementary File S1). The logarithm of the partition coecient (clogP)
values were calculated using Chemdraw 17.0 (Perkin Elmer, 2017, Waltham, MA, USA).
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3. Results
3.1. Chemistry
Smac activity has been correlated to binding to IAP proteins and mimicked by its N-terminal
four residue amide sequence (H-Ala-Val-Pro-Ile-NH2, 1, Figure 1) [50–52]. The purported turn
conformation adopted about the central Val-Pro dipeptide in this sequence has led to the synthesis of
various constrained analogs, exhibiting enhanced potency [12,53]. Noting the similar conformational
preferences of indolizidinone amino acid and aza-amino acyl proline turn mimics [54–57], and the
relative ease of synthesis of the latter, a series of aza-analogs were synthesized and certain were
shown to induce cell death by a caspase-9 mediated apoptotic pathway in cancer cell cultures [49,57].
Notably, aza-methanopipecolate and aza-cyclohexylglycine analogs 2 and 3 were synthesized using
pericyclic chemistry on the diazo dicarbonyl moiety of an azopeptide to examine the conformation
of the Val residue in 1 [49,58,59]. Specifically, the Alder-ene reaction of cyclohexadiene and the
Diels-Alder reaction of cyclopentadiene on N-(Cbz)azoglycinyl-proline benzhydrylamide 5 gave
the unsaturated azapeptides 6 and 7, which were hydrogenated with concomitant removal of
the benzyloxycarbonyl group, coupled to N-protected alanine, and deprotected (Scheme 1, [49]).
Considering the tolerance of N-methyl-alanine for alanine in the terminal position [60], a similar
approach was used to prepare N-methyl analog 4 by hydrogenation of azapeptide 7, coupling of the
resulting aza-cyclohexylglycinyl-L-proline benzhydrylamide (8) to N-(Boc)-N-methylalanine using
PyBop and cleavage of the Boc group with TFA in DCM. In cultured MCF7 breast cancer cells,
aza-cyclohexylglycine analog 3 induced up to 60% cell death relative to vehicle [49].
Scheme 1. Synthesis of Smac mimics 2 and 4 (dienes, azo- and aza-residues in blue).
3.1.1. Eect of Smac Mimic Administration In Vivo
We have previously reported that flies mutant in the BicC gene recapitulate key features of
PKD [3]. Considering that Smac mimics showed ecacy at reducing cysts in a rat PKD model [42],
the results of Smac mimic administration were tested in the BicC cystic flies using two dierent allelic
combinations. BicC mutant flies were obtained from genetic crosses of heterozygote parents consisting
of CyO-balanced flies containing Df(2L)RA5 (D, a BicC-encompassing deletion), and either the BicCYC33
or BicCIIF34 alleles similarly balanced with CyO. The BicCD/YC33 fly exhibits milder cystic defects than
the BicCD /IIF34 fly [3]. Straight-winged mutants (BicCD/YC33, BicCD/IIF34) from crosses were selected
within two days of eclosion to yield pools of 0–2 days old flies and aged for seven days (7–9 days
old), during which time the flies were kept well-fed by transferring to fresh vials twice (Figure 2).
Aged sibling flies were divided into fresh vials containing food spiked with either vehicle (water, 50 L)
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or one of the Smac analogs 1–4 at 20 M (50 L). Flies were transferred into identical fresh vials every
three days. After 20 days of treatment, the Malpighian tubules were micro-dissected from 27–29 day
old flies and analyzed ex vivo. Per each condition, cystic deformities were scored using 25–50 female
BicCD/IIF34 and BicCD/YC33 flies (i.e., 50–100 anterior and 50–100 posterior tubules). For each fly, cysts
which were found in the two anterior and two posterior tubules were scored and charted as nested plots
using the Prism 8.0 (Graphpad) software (Figures 3–6). Vehicle-treated flies presented several cysts in
both the anterior and posterior MTs, especially in the terminal and intermediate regions, and fewer
cysts in the proximal region, as reported previously [3]. Similar to PKD patients [1], a variable number
of cysts was found in dierent individuals [3]. In general, Smac-mimics appeared to reduce tubular
cysts in both BicC allelic combinations (Tables 1 and 2).
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Eects of Smac mimic administration were recorded as overall cyst reduction (Table 1, Table 2).
Nested plots were used to represent individual variability in cyst number in the analyzed fly populations.
Administration of peptide 1 to BicCD/YC33 flies (n = 50) reduced cystic deformities respectively by
44% and 20% (228 vs. 127 cysts and 276 vs. 220 cysts, p = 0.0005 and 0.0457) in the anterior and
posterior tubules, respectively (Table 1, Figure 3A,B). Administration of mimic 2 to BicCD/YC33 flies
(n = 50) reduced tubular cysts by 24% and 34% (216 vs. 165 cysts, p = 0.0324 and 244 vs. 162 cysts,
p = 0.0017) in the anterior and posterior tubules, respectively (Table 1, Figure 3A,B). Administration of
mimic 3 to BicCD/YC33 flies (n = 50) reduced cysts in the anterior and posterior tubules respectively by
21% and 34% (195 vs. 153 cysts, p = 0.1028 and 238 vs. 156 cysts, p = 0.0014, Table 1, Figure 3A,B).
Finally, administration of mimic 4 to BicCD/YC33 flies (n = 50) reduced cysts in the anterior and posterior
tubules respectively by 31% and 18% (134 vs. 93 cysts, p = 0.0553 and 152 vs. 124 cysts, p = 0.1877,
Table 1, Figure 3A,B).
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2, Figure 4A,B). Administration of mimic 2 to BicCΔ/IIF34 flies (n = 50) reduced cystic deformations by 
39% in the anterior (233 vs. 142 cysts, p = 0.0011) and by 33% in the posterior (302 vs. 202 cysts, p = 
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Figure 3. Smac-mimics red cysts in BicCD/YC33 flies. (A). Representative Malpighian tubules
micro-dissected from BicCD/YC33 flies treated with either vehicle or analogs 1, 2, 3, and 4 (indicated)
were photographed ex vivo. Arrows indicate cysts. In each image, anterior pairs are at the top, posterior
pairs at the bottom. Scale bar: 1 mm. (B). Nested plots depicting number of cysts found in the anterior
and posterior tubule pairs of vehicle- and Smac mimic-treated cystic flies (indicated), with mean and
standard deviation. P values (with Welch’s correction) are indicated. Treatments are indicated with
color: vehicle, grey; mimic 1, sepia; 2, blue; 3, dark pink; 4, brown.
The analogs were next administered to the BicCD/IIF34 flies carrying the allelic combination
which produced a more severe phenotype. Treatment with peptide 1 decreased cystic deformations
respectively by 44% and 37% (total 357 vs. 199 cysts and 433 vs. 272 cysts, p < 0.0001 and 0.0002,
respectively) in the anterior and posterior tubules of the micro-dissected BicCD/IIF34 flies (n = 50, Table 2,
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Figure 4A,B). Administration of mimic 2 to BicCD/IIF34 flies (n = 50) reduced cystic deformations by
39% in the anterior (233 vs. 142 cysts, p = 0.0011) and by 33% in the posterior (302 vs. 202 cysts,
p = 0.0020) tubules (Table 2, Figure 4A,B). Administration of mimic 3 to BicCD/IIF34 flies (n = 25) had a
milder and highly variable eect on the renal tubules and reduced cystic deformities by 11% (114 vs.
102 cysts, p = 0.6317) and 21% (155 vs. 122 cysts, p = 0.2285) in the anterior and posterior tubules
respectively (Table 2, Figure 4A,B), below statistical relevance thresholds. Finally, administration of
mimic 4 to BicCD/IIF34 flies (n = 50) reduced cysts in the anterior and posterior tubules by 40% (199 vs.
119 cysts, p = 0.0005) and 38% (243 vs. 151 cysts, p = 0.0002) respectively (Table 2, Figure 4A,B).
Parallel respective administration of analogs 1–4 to control, non-cystic OreR wild type flies did not
change MT morphology.
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Distinct MT regions in both the anterior and posterior tubules appeared to respond differentially 
to the Smac mimics. The cyst location was thus specifically mapped in the proximal, intermediate 
and terminal regions of the anterior and posterior tubules respectively (Table 3,4), and individual 
variable cyst numbers similarly plotted (Figure 5,6). Absolute numbers for the cysts in each region 
described below are listed in Table S2. 
3.1.2. Smac Mimics Differentially Affect Distinct Regions of the MTs 
Figure 4. Smac-mi ics reduce ts in BicCD/IIF34 flies. (A). Representative Malpighian tubules
micro-dissected from BicCD/IIF34 flies treated with either vehicle or analogs 1, 2, 3, and 4 (indicated)
were otographed ex vivo. Arrows indicate cysts. In each image, anterior pairs re at the top, posterior
pairs at the bottom. Scale bar: 1 m . (B). Nested plots depicting number of cysts found in the anterior
and posterior tubule pairs of vehicle- and Smac mimic-treated cystic flies (indicated), with mean and
standard deviation. P values (with Welch’s correction) are indicated. Treatments are indicated with
color: vehicle, grey; mimic 1, sepia; 2, blue; 3, dark pink; 4, brown.
Distinct MT regions in both the anterior and posterior tubules appeared to respond dierentially
to the Smac mimics. The cyst location was thus specifically mapped in the proximal, intermediate and
terminal regions of the anterior and posterior tubules respectively (Tables 3 and 4), and individual
variable cyst numbers similarly plotted (Figures 5 and 6). Absolute numbers for the cysts in each
region described below are listed in Table S2.
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Figure 5. Smac-mimics reduce cysts in BicCΔ/YC33 flies with varying regional specificity. Malpighian 
tubules from 50 BicCΔ/YC33 flies were micro-dissected after 20 days of treatment (age 27–29 days). Cysts 
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Figure 5. Smac-mimics reduce cysts in BicCD/YC33flies with varying regional specificity. Malpighian tubules
from 50 BicCD/YC33flies were micro-dissected after 20 days of treatment (age 27–29 days). Cysts were scored
ex vivo. For each fly, cysts numbers were recorded for the terminal, intermediate and proximal region
of the Malpighian tubules, independently for the anterior (left) and posterior (right) tubules. Flies were
administered either vehicle (water, grey) or Smac mimics 1 (A, sepia), 2 (B, blue), 3 (C, dark pink), and 4
(D, brown). Mean and standard deviation are indicated. Analogs 1 and 2 best reduced tubular cysts, mimic
3 was effective at reducing cysts in the terminal region of the anterior tubules and mimic 4 had a mild effect
in the intermediate region of both tubule pairs. P values (with Welch’s correction) are indicated. BicCD/YC33
flies exhibit the milder cystic defects.
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(right) tubules. Flies were administered either vehicle (water, grey) or Smac mimics 1 (A, sepia), 2 (B, 
Figure 6. Smac-mimics reduce cysts in BicCD/IIF34flies with varying regional specificity. Malpighian tubules
from 25 to 50 BicCD/IIF34flies were micro-dissected after 20 d of treatment (age 27–29 days). Cysts were
scored ex vivo. For each fly, cysts numbers were recorded for the terminal, intermediate and proximal region
of the Malpighian tubules, independently for the anterior (left) and posterior (right) tubules. Flies were
administered either vehicle (water, grey) or Smac mimics 1 (A, sepia), 2 (B, blue), 3 (C, dark pink), and 4
(D, brown). Mean and standard deviation are indicated. Peptide 1 was the most effective at reducing cysts
in the treated tubules. Mimics 2 and 4 showed great improvements in all regions except for the intermediate
region of the posterior tubules and mimic 3 showed a very mild to no effect in cyst reduction. P values
(with Welch’s correction) are indicated. BicCD/IIF34flies exhibit the more severe cystic defects.
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P values > 0.05 and corresponding percentages are italicized; n/s = not significant; n/a = no cysts.
3.1.2. Smac Mimics Dierentially Aect Distinct Regions of the MTs
Administration of peptide 1 to the milder allelic combination BicCD/YC33 (n = 50) reduced cysts
in the terminal and intermediate regions of the anterior tubules respectively by 53% and 34% (total
122 vs. 57, 104 vs. 69 cysts, p < 0.0001 and p = 0.0381, Table 3, Figure 5A). In the proximal region
of the anterior tubules, two cysts were found in the control versus one cyst in the treated samples,
precluding statistical analyses. In the posterior tubules, administration of peptide 1 diminished cysts
in the intermediate region by 26% (total 109 vs. 80 cysts, p = 0.0449). In the terminal and proximal
regions, a trend toward decreased cysts was observed, albeit without reaching a statistical threshold for
significance (respectively 108 vs. 84 cysts, 22% reduction, p = 0.1405, and 59 vs. 56 cysts, 5% reduction,
p = 0.7531, Table 3, Figure 5A).
Administration of peptide 1 to BicCD/IIF34flies reduced cysts in the anterior tubules by 40% and 48%
(total 156 vs. 94 and 193 vs. 100 cysts, p = 0.0038 and p < 0.0001) in the terminal and intermediate regions,
respectively (Table 4, Figure 6A). In the proximal region of the anterior tubules, a trend of cyst reduction was
observed, albeit fewer cysts (eight and five in vehicle- and peptide 1-treated tubules) and high individual
variability precluded a margin of confidence. In the posterior tubules, administration of peptide 1 reduced
cysts in the terminal, intermediate and proximal regions by 32%, 41% and 39% (total 180 vs. 122, 167 vs. 98,
86 vs. 52 cysts, p = 0.0022, 0.0008 and 0.0150), respectively (Table 4, Figure 6A).
Treatment with mimic 2 diminished cysts in the terminal region of the anterior tubules of BicCD/YC33
flies (n = 50) by 41% (114 vs. 67 cysts, p = 0.0006). In the intermediate region, a mild 5% reduction was
observed that did not approach a statistical significance threshold (102 vs. 97 cysts, p = 0.7599, Table 3,
Figure 5B). Precluding statistical analyses, no (control) and one cyst (mimic 2-treated) were detected
in the proximal region of the anterior tubules. In contrast, in the posterior tubule, administration of
mimic 2 reduced cysts in the terminal, intermediate and proximal regions by 32%, 29% and 47% (101 vs.
69 cysts, p = 0.0125, 96 vs. 68 cysts, p = 0.0389 and 47 vs. 25 cysts, p = 0.0057), respectively (Table 3,
Figure 5B).
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Administration of mimic 2 to the more severely cystic BicCD/IIF34 flies (n = 50) reduced cysts in the
terminal and intermediate regions of the anterior tubules by 37% and 41% (average 115 vs. 72 cysts,
p = 0.0161, 118 vs. 70 cysts, p = 0.0045), respectively. No cysts were found in the proximal regions
of control and treated tubules (Table 4, Figure 6B). Administration of mimic 2 reduced cysts in the
terminal and proximal regions of the posterior tubules by 32% and 43% (134 vs. 91 cysts, p = 0.0086 and
69 vs. 39 cysts, p = 0.0080), respectively. The intermediate region displayed a 27% reduction that
approached statistical significance threshold (99 vs. 72 cysts, p = 0.0703, Table 4, Figure 6B).
After treatment with mimic 3, the BicCD/YC33 flies (n = 50) harbored 40% fewer cysts in the terminal
region of the anterior tubules (99 vs. 59 cysts, p = 0.0041). In the intermediate region, the eect was
negligible (2% reduction, 96 vs. 94 cysts, p = 0.9072). No cysts were detected in the proximal region
of both control and treated tubules (Table 3, Figure 5C). On the contrary, administration of mimic
3 reduced strongly cysts in the terminal and intermediate regions of the posterior tubules by 45%
and 30% (100 vs. 55 cysts, p = 0.0007 and 90 vs. 63 cysts, p = 0.0465), respectively. The proximal
region displayed a trend towards cyst reduction with high individual variability (21% reduction, 48 vs.
38 cysts, p = 0.2431, Table 3, Figure 5C).
Mimic 3 did not ameliorate the more severely cystic BicCD/IIF34 flies (n = 25). After treatment with
mimic 3, the BicCD/IIF34 flies displayed respectively 11% and 9% (61 vs. 54 cysts, p = 0.6746 and 53 vs.
48 cysts, p = 0.7140) fewer cysts in the terminal and intermediate regions of the anterior tubules; no
cysts were observed in the proximal region of both control and treated tubules (Table 4, Figure 6C).
Similarly, mimic 3 caused respectively 21%, 10% and 40% (75 vs. 59 cysts, p = 0.2429, 50 vs. 45 cysts,
p = 0.7038 and 30 vs. 18 cysts, p = 0.1325) reductions in cysts in the terminal, intermediate and proximal
regions of the posterior tubules (Table 4, Figure 6C).
Mimic 4 reduced cysts in the intermediate region of the anterior tubules of BicCD/YC33 flies (n = 50)
by 36% (85 vs. 55 cysts, p = 0.0461). In the terminal region, a 20% decrease was observed, that did
not reach a threshold of statistical significance (49 vs. 39 cysts, p = 0.3377). No cysts were detected in
the proximal region of both control and treated tubules (Table 3, Figure 5D). Treatment with mimic 4
reduced cysts in the intermediate region of the posterior tubules by 33% (98 vs. 66 cysts, p = 0.0130),
but did not reduce cysts in the terminal and proximal regions (Table 3, Figure 5D).
Upon treatment with mimic 4, cysts were lessened in the terminal and intermediate regions of
the anterior tubules of BicCD/IIF34 flies (n = 50) by 38% and 42% (92 vs. 57 cysts, p = 0.0195 and 106 vs.
62 cysts, p = 0.0014), respectively (Table 4, Figure 6D). Precluding statistical analysis, only one cyst was
detected in the proximal region of control tubules and no cysts in the treated tubules. Administration of
mimic 4 reduced cysts in the terminal region of the posterior tubules by 51% (113 vs. 55 cysts, p <
0.0001). Less cysts were also scored in the intermediate and proximal regions, although values did
not reach the significance threshold (respectively 22% reduction, 90 vs. 70 cysts, p = 0.1231, and 35%
reduction, 40 vs. 26 cysts, p = 0.1069, Table 4, Figure 6D).
Ineective cyst reduction could be partly due to flies refusing to ingest the Smac mimics. To assess
their ingestion, the analogs were mixed with food and dye, and fed to the flies for four days. The green
dye could be seen through the semi-transparent abdominal cuticle of the BicC flies for all mimics,
confirming analog ingestion (Figure S1). As a measure of hydrophilicity, the clogP values were
calculated for the dierent Smac mimics (Figure 1) and found to be suciently low to be consistent
with absorption: 1 (0.7), 2 (3.9), 3 (5.0), 4 (5.4). Together these results support the conclusion that the
Smac analogs may have dierential activities and/or processing.
4. Discussion
A systematic analysis of the influences of the Smac mimic H-Ala-Val-Pro-Ile-NH2 (1) and
constrained analogs 2–4 on renal cystogenesis has been performed using the novel BicC fly model to
recapitulate features of PKD [3]. Two allelic combinations forBicCwere used that yield cystic phenotypes
of dierent severity, namely BicCD/YC33 and BicCD/IIF34. Previously, the Smac mimic GT13072 reduced
cystogenesis in a rat ADPKD model [42]. In the BicC flies, Smac mimics 1–4 ameliorated similarly the
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cystic condition with the strongest eects displayed in the more severely aected BicCD/IIF34 genotype.
Peptide 1 exhibited the highest overall ecacy reducing cyst occurrence by 20–44% across genotypes
at the anterior and posterior tubules. Moreover, aza-methanopipecolate 2 caused a 24–39% reduction
of cysts. Aza-cyclohexylglycine 3 displayed least ecacy, but still improved significantly the posterior
tubules of the BicCD/YC33 flies. The related N-methyl-alaninyl-aza-cyclohexylglycine analog 4 exhibited
dierential activity in the two BicC mutants, reducing cysts by ~40% in both tubules of the BicCD/IIF34
flies. In contrast, analog 4 only showed a trend towards reducing cysts in the anterior tubule of the
BicCD/YC33 flies close to the significance threshold (p = 0.0553). The Smac mimics tested appeared to
dierentially aect the anterior and posterior tubule pairs overall, consistent with the report of the
latter having distinct transcriptomes [10] and thus dierent physiological specialization. Mimics 1,
2 and 3 were found to induce death of 20% (1, 2) and 60% (3) of cultured MCF7 adenocarcinoma
cells [49]. Their ecacy in other PKD models and patients is unknown. Smac mimics function in
context-dependent ways, likely through dierent IAPs to aect apoptosis via several mechanisms [12].
Due to its methyl group, N-methyl-alaninyl-aza-cyclohexylglycine analog 4 was expected to be more
stable than aza-cyclohexylglycine 3 in vivo [61–63], which was consistent with the observed higher
cyst-reducing activity.
The tubular sections responded dierentially to treatment with the Smac mimics. The terminal
region consistently exhibited better improvement, especially in the weaker BicCD/YC33 allelic
combination. The flies were shown to ingest the Smac mimics. The clogP values of mimics 1–4
were also within the range consistent with eective absorption. The distinct pharmacological responses
observed at dierent regions of the MTs may be related to variability in absorption, metabolism and
response to Smac mimics within cystic cells in such regions. Regional specialization of fly MTs has
been observed despite the tubular epithelium being composed by only two major cell types (reviewed
in [9,64]). Cystogenesis may perturb cells and reduce the threshold for initiating cell death pathways
either through caspase-dependent apoptosis or the TNF signaling pathway. The contribution of
apoptosis to the early phases of ADPKD is a matter of debate [65]; however, the TNF pathway has been
implicated in ADPKD-type renal cystogenesis and suggested to be the primary target of Smac mimics in
a rat model of Pkd1-dependent ADPKD [42]. The results presented here predict that the BicC mutation
may feature dysregulated TNF signaling in the epithelial cells of the MTs, as observed in ADPKD-type
cystogenesis. The expression of TNF (Eiger) and TNF pathway components in the MT and their
respective contributions to tubular function are however unknown. The human BicC orthologue
BICC1 has been found to be genetically downstream of the main PKD1 gene [3]. The pharmacological
response to Smac mimics was herein demonstrated to be conserved in the fly illustrating further the
phenotypic and molecular similarities between PKD1-induced and BicC-induced renal cystogenesis.
Notably, pharmacological binding sites have been found to be conserved in Drosophila [66].
Chemical probing in the fly in vivo may thus rapidly pinpoint the involvement of specific pathways
with complementarity to genetic analyses, indicate conserved biological activity of drug-prototypes,
and provide a rapid read-out for eectiveness of pharmacological modulation of specific pathways
involved in cystic pathogenesis. The Smac mimics aected dierent tubular regions dierentially.
Considering that such specificity may be conserved to humans, the development of personalized
pharmacological treatments for cystic renal diseases such as PKD will benefit from precise knowledge
of the cyst-ameliorating potential of dierent Smac mimics.
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Chemicals were used as received from commercial sources without further purification unless 
stated otherwise. All glassware was stored in the oven or flame-dried and let cool under an inert 
atmosphere prior to use. Anhydrous solvents (DCM, and DMF) were obtained by passage through 
solvent filtration systems (Glass-Contour, Irvine, CA). Visualization of the developed 
chromatogram was performed by UV absorbance or staining with ceric ammonium molybdate or 
potassium permanganate solutions. Silica gel chromatography was performed using 230–400 mesh 
silica gel (Silicycle), and TLC was on glass-backed silica plates. Nuclear magnetic resonance 
spectra (1H, 13C) were recorded on Bruker AV 500 spectrometer. 1H NMR spectra were referenced 
to CD3OD (3.31 ppm) and 13C NMR spectra were measured in CD3OD (49.00 ppm) as specified 
below. Coupling constant, J values were measured in Hertz (Hz) and chemical shift values in parts 
per million (ppm). Infrared spectra were recorded in the neat on a Perkin Elmer Spectrum One 
FTIR instrument and are reported in reciprocal centimetres (cm-1). Accurate mass measurements 
were performed on a liquid chromatography−mass spectrometry (LC−MS) instrument from 
Agilent Technologies 1200 series in positive electrospray ionization (ESI)-time-of-flight (TOF) 
mode at the Université de Montréal Mass Spectrometry facility. Sodium and proton adducts ([M 
+ Na]+ and [M + H]+) were used for empirical formula confirmation. 
 
Reagents Used. Aza-Cyclohexaneglycinyl-L-Proline Benzhydrylamide was synthesized 
according to the literature method (Biopolymers, 2016, 106, 235-44). N-Boc-N-methyl-L-alanine 
and diisopropyl ethyl amine (DIEA) were purchased from Aldrich or Alfa Aesar and used without 
further purification. Benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate 
(PyBop) was purchased from GL BiochemTM, recrystallized prior to use from dry CH2Cl2/Et2O 
(melting point, 156 °C) and stored in the dark. 
 
N-methyl Alaninyl-aza-Cyclohexaneglycinyl-L-Proline Benzhydrylamide (4). A solution of Aza-
Cyclohexaneglycinyl-L-Proline Benzhydrylamide  (1 eq., 65 mg, 0.155 mmol) and DIEA (2 eq.,
40 mg, 53 !L, 0.309 mmol) was added to a solution of N-(tert-butoxycarbonyl)-N-methyl-L-
alanine (1.2 eq., 38 mg, 0.186 mmol) and PyBOP (1.5 eq., 121 mg, 0.233 mmol) in DMF (3
mL), and stirred overnight. The volatiles were removed under vacuum. The residue was
dissolved in EtOAc (10 mL), washed with 5 mL of saturated aqueous NaHCO3, followed by
brine (10 mL), dried over Na2SO4, filtered, and evaporated. Without further purification, the
residue was dissolved in a 25% solution of TFA in dichloromethane (2 mL), and stirred for 2 h.
The volatiles were removed under vacuum. The residue was dissolved in CH2Cl2 and the
solution was evaporated. The residue was suspended in 2 mL of 1N HCl, stirred for 30 min, and
freeze-dried to give the hydrochloride salt as off white solid. The crude sample was purified by
RP-HPLC on a reverse-phase Gemini® C18 column (Phenomenex® Inc., pore size: 110 Å,
particle size: 5 µm, 250 x 21.2 mm) using a binary solvent system consisting of a gradient of 5%-
60% MeOH (0.1% FA) in water (0.1% FA), with a flow rate of 10.0 mL/min, and UV detection
at 214 nm. The desired fractions were combined and freeze-dried to white fluffy powder:
azapeptide 2 (5.2 mg, 0.01 mmol, 7%, 2-steps): mp 93-94 °C; 1H NMR (500 MHz, MeOD) !
8.40 (s, 1H), 7.45 – 7.20 (m, 10H), 6.24 (s, 1H), 4.56 – 4.42 (m, 1H), 4.05 – 3.88 (m, 1H), 3.69 –
3.42 (m, 2H), 2.59 – 2.43 (m, 3H), 2.43 – 2.31 (m, 1H), 2.26 – 2.14 (m, 1H), 2.14 – 2.00 (m,
1H), 2.00 – 1.91 (m, 1H), 1.91 – 1.62 (m, 6H), 1.53 – 1.36 (m, 5H), 1.35 – 1.03 (m, 5H); 13C
NMR (125 MHz, MeOD) ! 174.1, 171.2, 161.4, 143.2, 139.1, 129.5 (2C), 129.4 (2C), 129.3
(2C), 128.8 (2C), 128.4, 128.2, 63.6, 57.9, 57.4, 49.6, 31.5, 31.3, 30.8, 26.9, 26.72 (2C), 26.69
(2C), 26.5, 17.5; IR (neat) vmax/cm-1 2929, 1638, 1532, 1495, 1449, 1406, 1344, 1323, 1095;
HRMS m/z calculated for C29H40N5O3 [M+H]+ 506.3126; found 506.3139.
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1 2 0 0 2 2 1 1 2 0 0 0 3 2
2 3 5 0 1 3 3 2 0 2 0 0 1 1
3 3 4 1 2 2 0 3 0 0 0 2 2 2
4 4 5 0 4 4 1 4 1 1 0 2 2 0
5 0 0 0 0 0 0 5 0 0 0 0 1 0
6 4 1 0 0 3 0 6 0 0 0 0 2 0
7 2 2 0 2 2 0 7 0 0 0 0 0 0
8 4 5 0 2 3 1 8 2 3 0 2 1 2
9 3 2 0 1 3 0 9 0 0 0 3 0 1
10 0 2 1 1 3 0 10 0 2 0 3 2 2
11 2 0 0 1 4 0 11 1 3 0 3 2 2
12 2 2 0 3 3 2 12 0 5 0 3 4 4
13 0 0 0 0 0 2 13 2 2 0 2 4 1
14 3 4 0 2 3 2 14 2 3 0 2 0 1
15 5 6 0 5 7 1 15 4 5 0 1 3 1
16 6 3 0 1 3 2 16 2 4 0 2 2 2
17 5 6 0 4 3 0 17 0 0 0 0 0 0
18 5 1 0 0 5 2 18 0 2 0 4 2 2
19 4 3 0 4 2 2 19 0 0 0 2 0 0
20 2 5 0 4 0 0 20 0 1 0 4 2 2
21 0 3 0 3 2 0 21 0 0 0 2 1 2
22 2 2 0 4 2 1 22 0 0 0 0 0 2
23 1 1 0 0 0 2 23 0 0 0 0 0 0
24 2 3 0 6 4 0 24 3 2 0 2 1 2
25 5 1 0 5 2 1 25 0 0 0 0 3 0
26 0 0 0 3 3 2 26 4 2 0 4 4 2
27 3 0 0 0 2 2 27 2 2 0 0 0 1
28 3 3 0 0 0 3 28 0 0 0 2 2 0
29 4 3 0 0 0 2 29 0 0 0 1 3 1
30 3 5 0 3 5 1 30 2 0 0 2 1 1
31 2 2 0 5 5 2 31 4 4 0 4 3 0
32 0 0 0 0 0 0 32 2 2 0 2 3 1
33 2 1 0 1 1 2 33 3 2 0 0 0 0
34 2 2 0 4 1 2 34 3 1 0 3 3 1
35 6 4 0 4 2 2 35 0 0 0 0 0 2
36 3 2 0 5 2 1 36 0 0 0 3 1 1
37 7 2 0 2 2 2 37 2 2 0 1 1 0
38 3 2 0 2 2 2 38 1 0 0 0 0 2
39 3 2 0 3 1 0 39 0 0 0 0 3 0
40 2 1 0 2 2 0 40 2 2 1 5 3 2
41 3 0 0 1 4 2 41 1 1 0 1 2 0
42 2 0 0 0 0 2 42 0 0 0 0 0 0
43 2 0 0 2 0 0 43 2 5 0 4 2 1
44 1 3 0 2 3 2 44 2 4 0 5 2 0
45 0 2 0 3 2 1 45 1 1 0 3 1 1
46 0 0 0 2 3 1 46 2 1 0 2 1 1
47 0 0 0 3 0 0 47 2 0 0 0 0 2
48 1 3 0 1 1 2 48 0 3 0 0 2 3
49 1 0 0 0 1 2 49 1 1 0 0 2 1
50 0 1 0 3 2 1 50 2 1 0 3 3 2


























1 2 2 0 5 5 2 1 1 2 1 2 2 2
2 0 0 0 0 0 0 2 0 0 0 2 4 2
3 2 1 0 1 1 2 3 0 0 0 0 3 1
4 2 2 0 4 1 2 4 1 2 0 1 1 2
5 6 4 0 4 2 2 5 2 2 0 0 2 2
6 3 2 0 5 2 1 6 0 2 0 0 0 1
7 7 2 0 2 2 2 7 0 0 0 1 0 1
8 3 2 0 2 2 2 8 0 0 0 5 1 2
9 3 2 0 3 1 0 9 0 0 0 0 0 0
10 2 1 0 2 2 0 10 0 0 0 0 0 0
11 3 0 0 1 4 2 11 0 3 0 2 2 1
12 4 3 0 2 0 1 12 2 2 0 3 3 0
13 2 0 0 0 2 0 13 1 0 0 3 0 0
14 2 3 0 1 2 1 14 0 0 0 0 0 0
15 0 0 0 0 0 1 15 1 0 0 1 0 0
16 1 1 0 1 0 1 16 3 3 0 2 2 0
17 0 5 0 3 5 1 17 2 5 0 2 1 0
18 1 3 0 3 2 2 18 2 4 0 2 0 1
19 3 6 0 1 1 0 19 0 0 0 0 0 0
20 0 0 0 0 0 0 20 1 3 0 1 0 0
21 3 4 0 3 4 0 21 2 1 0 2 0 0
22 1 3 0 2 3 1 22 2 2 0 0 1 0
23 1 2 0 1 0 1 23 3 3 0 2 2 0
24 2 4 0 2 3 2 24 1 0 0 2 2 0
25 1 6 0 4 5 0 25 2 0 0 0 1 0
26 1 4 0 3 2 1 26 2 3 0 1 2 0
27 3 1 0 2 1 1 27 3 1 0 0 1 0
28 3 2 0 3 3 0 28 4 5 0 1 0 0
29 2 4 0 2 3 1 29 0 3 0 1 3 0
30 0 0 0 3 4 1 30 0 3 0 2 3 0
31 3 2 0 1 2 1 31 1 2 0 4 2 0
32 5 2 0 4 2 1 32 0 0 0 0 0 0
33 4 3 0 1 1 1 33 2 1 0 1 1 0
34 3 1 0 1 0 1 34 2 5 0 2 5 0
35 3 2 0 2 2 0 35 2 4 0 2 2 0
36 2 0 0 3 4 0 36 3 2 0 0 1 1
37 1 1 0 2 2 0 37 1 4 0 1 1 1
38 4 2 0 3 1 1 38 0 6 0 3 2 0
39 2 2 0 1 1 2 39 1 4 0 0 2 0
40 3 3 0 3 2 2 40 3 1 0 1 1 0
41 2 3 0 4 4 2 41 2 2 0 2 2 1
42 2 2 0 2 1 2 42 2 0 0 1 2 0
43 5 2 0 2 3 2 43 2 3 0 1 1 0
44 2 0 0 2 1 0 44 2 5 0 2 2 2
45 2 1 0 2 2 1 45 2 0 0 1 0 0
46 1 1 0 0 0 0 46 3 3 0 2 2 1
47 3 1 0 1 1 1 47 1 1 0 3 0 2
48 2 3 0 2 3 0 48 0 0 0 0 0 0
49 0 0 0 0 0 0 49 2 2 0 3 4 2
50 2 2 0 0 2 0 50 1 3 0 2 2 0


























1 2 2 0 5 5 2 1 1 3 0 0 2 2
2 0 0 0 0 0 0 2 0 0 0 0 0 2
3 2 1 0 1 1 2 3 0 0 0 0 0 2
4 2 2 0 4 1 2 4 0 0 0 0 2 1
5 6 4 0 4 2 2 5 1 2 0 0 1 0
6 3 2 0 5 2 1 6 2 3 0 0 1 2
7 7 2 0 2 2 2 7 0 0 0 0 0 0
8 3 2 0 2 2 2 8 1 4 0 1 2 0
9 3 2 0 3 1 0 9 0 0 0 0 0 0
10 2 1 0 2 2 0 10 1 1 0 3 1 0
11 3 0 0 1 4 2 11 0 0 0 1 1 2
12 2 0 0 0 0 2 12 1 4 0 1 2 2
13 2 0 0 2 0 0 13 0 0 0 0 0 2
14 1 3 0 2 3 2 14 2 6 0 1 2 1
15 0 2 0 3 2 1 15 2 6 0 3 2 2
16 0 0 0 2 3 1 16 0 0 0 0 0 2
17 0 0 0 3 0 0 17 3 2 0 3 2 1
18 1 3 0 1 1 2 18 2 3 0 1 2 1
19 1 0 0 0 1 2 19 2 3 0 0 0 2
20 0 1 0 3 2 1 20 2 5 0 2 2 1
21 4 3 0 2 0 1 21 3 3 0 2 5 0
22 2 0 0 0 2 0 22 2 4 0 3 3 3
23 2 3 0 1 2 1 23 0 0 0 0 0 0
24 0 0 0 0 0 1 24 1 1 0 0 1 0
25 1 1 0 1 0 1 25 2 2 0 2 2 1
26 0 5 0 3 5 1 26 1 2 0 0 1 1
27 1 3 0 3 2 2 27 3 2 0 2 2 0
28 3 6 0 1 1 0 28 1 3 0 2 2 0
29 0 0 0 0 0 0 29 1 0 0 0 0 0
30 3 4 0 3 4 0 30 3 3 0 2 4 0
31 1 3 0 2 3 1 31 0 0 0 0 0 0
32 1 2 0 1 0 1 32 1 5 0 0 3 0
33 2 4 0 2 3 2 33 0 0 0 0 0 0
34 1 6 0 4 5 0 34 0 0 0 0 0 0
35 1 4 0 3 2 1 35 2 1 0 2 1 1
36 3 1 0 2 1 1 36 3 2 0 0 3 1
37 3 2 0 3 3 0 37 0 0 0 2 0 0
38 2 4 0 2 3 1 38 2 3 0 4 1 0
39 0 0 0 3 4 1 39 3 2 0 3 2 0
40 3 2 0 1 2 1 40 1 2 0 1 1 1
41 5 2 0 4 2 1 41 2 2 0 2 3 0
42 4 3 0 1 1 1 42 0 0 0 1 0 0
43 3 1 0 1 0 1 43 0 5 0 4 1 1
44 3 2 0 2 2 0 44 0 1 0 1 0 0
45 2 0 0 3 4 0 45 3 4 0 1 0 0
46 1 1 0 2 2 0 46 2 2 0 3 3 1
47 4 2 0 3 1 1 47 2 0 0 2 2 3
48 2 2 0 1 1 2 48 0 0 0 0 0 0
49 2 3 0 1 1 0 49 0 0 0 0 0 0
50 0 0 0 0 0 0 50 1 3 0 0 1 0


























1 0 2 0 0 1 0 1 0 3 0 0 1 0
2 0 0 0 0 0 0 2 0 0 0 0 0 0
3 0 2 0 2 1 0 3 0 0 0 0 0 0
4 1 3 0 0 0 0 4 0 0 0 0 0 1
5 0 0 0 3 2 0 5 2 1 0 2 2 0
6 0 1 0 0 3 0 6 1 1 0 1 1 0
7 0 0 0 0 3 0 7 0 0 0 0 0 0
8 1 7 0 2 2 0 8 0 2 0 0 1 0
9 0 0 0 0 0 0 9 1 2 0 1 1 0
10 2 2 0 2 3 0 10 0 0 0 0 0 0
11 0 0 0 1 0 0 11 0 0 0 0 1 0
12 0 3 0 0 4 1 12 0 3 0 2 3 0
13 4 5 0 3 2 0 13 1 0 0 1 0 0
14 0 2 0 0 0 0 14 0 0 0 1 3 1
15 1 4 0 2 4 2 15 2 0 0 0 0 0
16 0 2 0 1 2 0 16 2 2 0 0 2 1
17 1 0 0 1 1 0 17 1 1 0 2 2 0
18 2 0 0 0 2 0 18 0 0 0 1 0 0
19 2 6 0 0 4 0 19 0 0 0 2 1 1
20 0 0 0 0 2 0 20 0 2 0 1 3 0
21 2 0 0 1 0 0 21 2 2 0 1 3 0
22 0 3 0 1 2 0 22 0 5 0 2 4 1
23 2 2 0 1 2 0 23 0 2 0 2 3 1
24 2 0 0 1 2 0 24 2 0 0 0 1 0
25 0 2 0 1 2 0 25 2 4 0 1 2 0
26 0 0 0 0 1 0 26 1 1 0 2 3 0
27 0 2 0 2 2 0 27 0 0 0 0 0 0
28 1 0 0 0 1 0 28 1 2 0 1 1 0
29 1 2 0 2 3 0 29 0 1 0 0 1 0
30 3 4 0 3 5 1 30 0 2 0 2 1 1
31 3 1 0 2 3 0 31 1 1 0 1 3 0
32 2 3 0 2 3 0 32 0 0 0 0 0 0
33 1 2 0 1 1 1 33 3 3 0 3 4 0
34 2 1 0 3 3 0 34 3 1 0 3 4 0
35 2 0 0 1 2 0 35 0 0 0 0 0 1
36 3 3 0 1 2 0 36 2 1 0 1 1 1
37 3 5 0 0 3 0 37 0 0 0 0 0 0
38 1 4 0 1 1 1 38 2 2 0 1 4 0
39 0 0 0 1 2 0 39 0 1 0 0 1 0
40 1 0 0 0 2 0 40 0 0 0 0 0 0
41 1 2 0 0 3 0 41 0 0 0 0 0 0
42 0 0 0 0 0 0 42 0 1 0 1 2 1
43 1 3 0 1 3 0 43 0 0 0 0 0 0
44 1 1 0 1 2 1 44 0 2 0 1 1 0
45 1 1 0 1 2 0 45 0 0 0 0 0 0
46 0 0 0 0 2 0 46 1 1 0 0 1 0
47 1 1 0 1 2 0 47 3 0 0 1 0 0
48 0 0 0 0 0 1 48 3 1 0 6 2 0
49 1 3 0 1 4 0 49 2 4 0 2 2 0
50 0 1 0 0 2 0 50 1 0 0 2 1 1
Total # of cysts 49 85 0 46 98 8 286 Total # of cysts 39 54 0 47 66 11 217


























1 0 5 0 3 4 0 1 0 3 0 2 2 3
2 3 10 2 4 5 1 2 2 5 3 3 6 1
3 3 8 1 4 6 4 3 1 4 0 5 5 4
4 4 6 0 4 4 5 4 3 5 0 4 3 1
5 5 8 0 4 7 1 5 0 0 2 3 0 0
6 5 6 0 4 5 2 6 0 0 0 0 0 2
7 9 5 1 7 9 5 7 2 3 0 4 2 1
8 7 7 1 7 7 7 8 2 5 0 6 3 4
9 4 3 0 5 3 3 9 0 0 0 0 0 1
10 5 9 0 3 6 1 10 1 2 0 4 5 1
11 0 4 0 4 4 3 11 1 3 0 3 2 2
12 3 5 0 5 2 0 12 0 0 0 0 0 0
13 3 4 0 4 4 2 13 2 3 0 2 4 2
14 2 7 1 6 5 3 14 4 6 0 5 3 1
15 7 11 1 5 5 2 15 2 2 0 3 4 3
16 4 6 1 6 6 3 16 2 3 0 3 4 2
17 5 4 0 5 4 2 17 0 0 0 0 2 0
18 6 4 0 4 7 2 18 1 0 0 3 1 1
19 4 5 0 5 5 2 19 4 3 0 3 3 1
20 4 4 0 3 5 4 20 3 3 0 6 2 2
21 3 5 0 6 6 0 21 0 0 0 1 1 2
22 0 1 0 2 2 1 22 3 3 0 0 0 0
23 0 0 0 2 2 3 23 0 2 0 3 2 0
24 0 0 0 0 0 0 24 3 3 0 4 2 2
25 1 5 0 0 0 0 25 0 0 0 0 0 2
26 1 3 0 2 1 0 26 0 0 0 0 0 0
27 5 4 0 4 1 0 27 0 0 0 0 0 0
28 4 5 0 4 4 1 28 2 3 0 0 3 0
29 2 2 0 4 2 2 29 4 2 0 0 2 3
30 2 1 0 5 2 0 30 0 2 0 2 2 0
31 2 3 0 4 2 2 31 0 0 0 0 0 0
32 9 2 0 9 0 3 32 3 3 0 2 4 0
33 6 0 0 3 5 2 33 2 3 0 4 3 0
34 4 3 0 3 3 2 34 1 1 0 3 3 0
35 0 0 0 0 0 0 35 1 2 0 3 3 0
36 0 0 0 0 0 0 36 6 2 0 4 0 2
37 2 3 0 3 2 1 37 3 0 0 3 3 2
38 2 4 0 3 4 1 38 1 1 0 3 1 0
39 5 1 0 6 1 2 39 8 1 0 2 1 1
40 7 3 0 5 3 2 40 0 0 0 0 0 0
41 2 3 0 4 6 3 41 1 3 0 3 2 0
42 2 1 0 2 2 0 42 4 0 0 6 4 0
43 2 5 0 3 5 3 43 3 4 0 3 1 0
44 2 2 0 3 3 0 44 1 1 0 0 0 2
45 0 0 0 2 0 1 45 2 4 0 3 1 0
46 1 2 0 2 0 1 46 2 0 0 2 2 1
47 4 5 0 1 5 2 47 4 1 0 3 1 2
48 1 3 0 2 1 0 48 4 4 0 4 3 1
49 0 4 0 1 0 0 49 3 3 0 3 1 0
50 4 2 0 3 2 2 50 3 2 0 2 2 0


























1 0 1 0 2 2 1 1 0 0 0 0 0 0
2 0 0 0 2 2 3 2 2 4 0 3 0 0
3 0 0 0 0 0 0 3 0 0 0 0 0 0
4 1 5 0 0 0 0 4 1 2 0 3 0 0
5 1 3 0 2 1 0 5 0 0 0 0 0 2
6 5 4 0 4 1 0 6 0 0 0 4 2 2
7 4 5 0 4 4 1 7 0 0 0 0 2 0
8 2 2 0 4 2 2 8 0 3 0 3 1 0
9 2 1 0 5 2 0 9 0 4 0 0 3 2
10 2 3 0 4 2 2 10 0 0 0 0 0 0
11 9 2 0 9 0 3 11 0 0 0 0 0 0
12 6 0 0 3 5 2 12 3 1 0 1 3 0
13 4 3 0 3 3 2 13 4 4 0 5 3 2
14 0 0 0 0 0 0 14 2 1 0 1 0 0
15 0 0 0 0 0 0 15 2 3 0 3 3 2
16 2 3 0 3 2 1 16 2 0 0 0 1 0
17 2 4 0 3 4 1 17 1 0 0 0 0 0
18 5 1 0 6 1 2 18 1 3 0 1 0 1
19 7 3 0 5 3 2 19 4 2 0 4 2 0
20 2 3 0 4 6 3 20 1 0 0 2 2 1
21 2 1 0 2 2 0 21 4 1 0 4 0 0
22 2 5 0 3 5 3 22 2 3 0 2 1 1
23 2 2 0 3 3 0 23 0 0 0 0 0 1
24 0 0 0 2 0 1 24 1 0 0 1 1 0
25 1 2 0 2 0 1 25 4 2 0 4 1 1
26 4 5 0 1 5 2 26 3 1 0 3 3 1
27 1 3 0 2 1 0 27 0 0 0 0 0 0
28 0 4 0 1 0 0 28 2 1 0 2 3 1
29 4 2 0 3 2 2 29 0 1 0 2 0 0
30 0 1 0 2 2 1 30 3 1 0 2 1 3
31 0 0 0 2 2 3 31 1 0 0 2 0 2
32 0 0 0 0 0 0 32 2 1 0 2 2 3
33 4 2 0 2 2 3 33 0 5 0 2 3 3
34 2 6 0 3 4 5 34 2 0 0 2 0 0
35 3 4 0 4 2 1 35 0 0 0 1 0 0
36 2 2 0 2 1 0 36 2 2 0 2 5 1
37 3 0 0 2 1 2 37 4 2 0 1 5 1
38 0 3 0 2 3 2 38 1 1 0 2 3 2
39 5 5 0 2 2 2 39 0 0 0 0 0 0
40 0 3 0 2 2 2 40 2 4 0 5 4 0
41 3 2 0 1 3 3 41 1 5 0 3 3 2
42 2 4 0 3 2 2 42 3 0 0 2 3 2
43 3 3 0 3 2 0 43 1 3 0 4 2 3
44 2 0 0 2 0 1 44 2 2 0 4 1 0
45 1 2 0 2 1 2 45 1 5 0 3 3 0
46 3 4 0 3 3 1 46 4 1 0 4 2 0
47 4 4 0 5 2 1 47 1 2 0 0 2 0
48 5 3 0 5 3 3 48 3 0 0 1 0 0
49 0 0 0 3 2 0 49 0 0 0 0 0 0
50 3 3 0 2 2 1 50 0 0 0 1 2 0


























1 0 1 0 2 2 1 1 7 2 0 3 2 0
2 0 0 0 2 2 3 2 4 1 0 4 0 0
3 0 0 0 0 0 0 3 0 0 0 0 0 0
4 1 5 0 0 0 0 4 2 2 0 2 2 0
5 1 3 0 2 1 0 5 8 4 0 4 4 1
6 5 4 0 4 1 0 6 4 3 0 4 3 0
7 4 5 0 4 4 1 7 3 0 0 2 3 2
8 2 2 0 4 2 2 8 0 0 0 0 0 0
9 2 1 0 5 2 0 9 3 3 0 4 2 3
10 2 3 0 4 2 2 10 3 6 0 4 4 0
11 9 2 0 9 0 3 11 5 6 0 3 4 1
12 6 0 0 3 5 2 12 0 0 0 0 0 2
13 4 3 0 3 3 2 13 0 0 0 0 0 0
14 0 0 0 0 0 0 14 3 6 0 3 7 2
15 0 0 0 0 0 0 15 1 3 0 2 0 3
16 2 3 0 3 2 1 16 0 0 0 2 0 0
17 2 4 0 3 4 1 17 1 1 0 1 0 0
18 5 1 0 6 1 2 18 2 0 0 6 4 0
19 7 3 0 5 3 2 19 0 0 0 0 0 0
20 2 3 0 4 6 3 20 4 0 0 4 2 0
21 2 1 0 2 2 0 21 0 3 0 1 1 1
22 2 5 0 3 5 3 22 1 5 0 5 4 3
23 2 2 0 3 3 0 23 0 1 0 2 2 0
24 0 0 0 2 0 1 24 0 0 0 0 0 0
25 1 2 0 2 0 1 25 3 2 0 3 1 0


























1 0 2 0 2 0 0 1 2 1 0 3 4 2
2 1 4 0 3 4 0 2 3 1 0 3 2 0
3 3 3 0 3 2 0 3 3 0 0 2 1 0
4 3 3 0 3 5 0 4 0 0 0 0 0 0
5 0 1 0 2 0 0 5 6 4 0 0 4 0
6 5 1 0 5 0 0 6 2 0 0 0 0 1
7 3 3 1 4 1 0 7 3 1 0 0 2 0
8 0 0 0 0 0 0 8 2 2 0 3 0 0
9 2 1 0 2 2 0 9 0 0 0 0 2 1
10 2 6 0 4 2 0 10 2 2 0 2 1 0
11 1 1 0 3 0 0 11 0 0 0 1 0 1
12 2 1 0 0 3 1 12 1 0 0 1 1 1
13 5 3 0 3 2 0 13 1 3 0 1 2 0
14 4 3 0 6 3 2 14 5 2 0 3 5 0
15 5 2 0 4 4 0 15 0 0 0 0 2 0
16 0 4 0 0 0 2 16 0 0 0 0 0 0
17 1 1 0 2 2 0 17 0 0 0 0 0 0
18 4 1 0 4 4 0 18 0 0 0 1 0 0
19 0 0 0 0 0 0 19 2 2 0 1 1 0
20 3 4 0 5 5 2 20 3 4 0 3 3 0
21 2 1 0 2 1 2 21 1 0 0 1 1 0
22 1 4 0 5 2 2 22 2 3 0 1 2 0
23 2 2 0 3 2 2 23 0 0 0 0 0 0
24 1 0 0 2 1 2 24 0 1 0 1 2 2
25 2 1 0 5 2 0 25 1 1 0 1 1 0
26 1 2 0 3 2 0 26 2 4 0 0 2 0
27 4 2 0 3 2 2 27 0 2 0 1 1 1
28 0 1 0 2 1 1 28 1 3 0 0 1 2
29 2 1 0 0 0 1 29 1 2 0 0 3 0
30 1 2 0 2 2 2 30 0 3 0 0 0 1
31 2 0 0 1 2 0 31 0 2 0 0 1 1
32 0 2 0 2 2 0 32 1 1 0 2 2 0
33 3 0 0 1 4 2 33 0 1 0 2 2 3
34 2 1 0 0 1 0 34 1 0 0 2 1 0
35 3 4 0 1 1 0 35 1 0 0 3 0 1
36 0 1 0 1 1 2 36 3 1 0 2 1 1
37 1 2 0 3 1 0 37 0 0 0 0 0 0
38 0 3 0 1 2 1 38 2 1 0 0 1 0
39 0 1 0 1 0 0 39 0 2 0 1 3 1
40 1 4 0 2 2 0 40 0 3 0 2 1 0
41 2 2 0 2 2 1 41 0 1 0 2 3 0
42 0 4 0 1 0 0 42 0 2 0 2 2 0
43 0 2 0 1 4 1 43 0 2 0 0 1 1
44 3 1 0 1 1 0 44 1 2 0 3 2 2
45 1 2 0 2 1 1 45 2 0 0 1 1 2
46 4 3 0 3 3 2 46 1 1 0 2 2 1
47 5 5 0 2 2 2 47 0 0 0 0 1 0
48 0 3 0 2 2 2 48 0 0 0 0 0 0
49 3 2 0 1 3 3 49 0 0 0 1 0 0
50 2 4 0 3 2 2 50 2 2 0 1 3 1
Total # of cysts 92 106 1 113 90 40 442 Total # of cysts 57 62 0 55 70 26 270
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Appendix II 
Introduction to the Appendix II: The following review article on the use of Drosophila to 
model renal disease includes 154 years of scientific literature on Malpighian tubules, dating from 
1864 to 2018. This was the first comprehensive and up to date review comparing the Drosophila 
and the human renal systems focusing on the conserved features that could be used to model 
renal disease. The review especially focused on the Malpighian tubules, which are equivalent to 
the tubular part of a vertebrate nephron and on selected functional aspects of the nephrocytes, 
Drosophila renal cells which perform similar readsorptive functions to the vertebrate glomerular 
podocytes and have been recently reviewed elsewhere. Written at the start of my M.Sc., this 
review enabled me to get acquainted with the field of renal function studies and the intricacies of 
modeling biological renal pathways in Drosophila. This review could be useful for colleagues 
engaged in comparative and/or fluid transport and renal function studies, as well as those 
interested in drug screening in Drosophila. Finally, similar to human kidneys, the Malpighian 
tubules are insect detoxification systems implicated in insecticide response. Therefore, 
improving our understanding of their functions and physiology may be helpful for insect 
management efforts.  
Note: This review paper was published as “Millet-Boureima C., Porras Marroquin J., and 
Gamberi C. 2018. BioMed Research International, vol. 2018, Article ID 5697436” and the 
entirety of its content is being presented in this thesis. DOI. In the published article, the term 
Malpighian tubules is abbreviated as MTs. 
Contribution of authors: 
I wrote the first draft of the manuscript and contributed extensively to the final text. 
Jessica Porras Marroquin provided a section on nephrocytes (Section 2.3). 
Dr. Chiara Gamberi wrote the sections on PKD (Sections 2.4.2 and 2.4.3). 
Dr. Chiara Gamberi and I edited the manuscript. 
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Detoxification is a fundamental function for all living organisms that need to excrete catabolites and toxins tomaintain homeostasis.
Kidneys are major organs of detoxification that maintain water and electrolyte balance to preserve physiological functions of
vertebrates. In insects, the renal function is carried out by Malpighian tubules and nephrocytes. Due to differences in their
circulation, the renal systems of mammalians and insects differ in their functional modalities, yet carry out similar biochemical
and physiological functions and share extensive genetic and molecular similarities. Evolutionary conservation can be leveraged to
model specific aspects of the complex mammalian kidney function in the genetic powerhouse Drosophila melanogaster to study
how genes interact in diseased states. Here, we compare the human and Drosophila renal systems and present selected fly disease
models.
1. Introduction
Defective kidney function can lead to potentially lethal
end-stage renal disease (ESRD) and chronic kidney disease
(CKD), for which therapeutic options are limited. ESRD
and CKD may be remedied by dialysis and renal replace-
ment therapy (renal transplant), which are both costly [1]
and greatly affect the quality of life of both patients and
their families. The complexity of the human kidney has
posed a formidable challenge to experimental probing for
many pathologies. In many cases disease progression is
well described; however, the underlying mechanisms at the
molecular and cellular levels are incompletely understood,
which affects our capacity to design remedial therapeutics.
Animal model research on kidney disease has traditionally
used rodents for their mammalian-type kidney similar to
the human one. However, rodent and human kidneys also
share the same complexity, which challenges experimenta-
tion. Zebrafish, featuring a streamlined pronephros, has also
been used to model renal disease, albeit less frequently, in
part because of its adaptation to an aquatic environment.
With an open circulatory system, the fly’s renal system
is aglomerular and urine formation is based on active
transport rather than selective readsorption [2]. However,
Drosophila is a clear evolutionary intermediate towards the
glomerular kidney, with recognizable cell types responsible
for fulfilling the kidney’s main functions: detoxification,
filtration, and endocytosis [3, 4]. The small body size and the
fastest filtration rate known [5] allow flies to have separate
compartments for renal function: the Malpighian Tubules
(MTs), which are analogous to the renal tubules [6], and
two clusters of nephrocytes within the body cavity, which are
analogous to podocytes in the glomerular kidney. Because of
extensive functional similarities, the fly has been successfully
used to model aspects of mammalian renal function. We
will compare the human and Drosophila renal systems and
discuss the strategic use of fly modeling of human renal
disease.
2. The Human Renal Filtration System
The human kidneys, found in the mid to lower back of the
trunk on each side of the spine, are bean-shaped organs
roughly the size of a person’s own fist. Composed of two
main layers, the cortex and the medulla, they play a leading
role in blood filtration, solute reabsorption, and metabolic
waste excretion, which result in urine production.The kidney
medulla contains so-called renal pyramids, conical regions
collectively holding about onemillion functional units, which
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Figure 1: Comparison of the human podocyte and the Drosophila nephrocyte slit diaphragms. Selected evolutionary conserved proteins are
indicated.The same symbols indicate orthologous proteins between human andDrosophila. In the fly, Duf was found to directly interact with
Pyd and Sns with podocin ortholog Mec-2 [6].
are called nephrons. The nephrons span both cortex and
medulla, starting and ending in the former, with the latter
containing variable lengths of the central portion of the
tubule. Nephronsmodify the filtered fluid and produce urine,
which drains into collecting tubules (also called collecting
ducts) that in turn fuse into larger ducts that empty into the
minor calyx, the ureter and, eventually, the bladder.
Each nephron consists of a tubule closed at one end
and enlarged into the cup-like Bowman’s capsule, which
surrounds a tuft of capillaries called glomerulus. Together, the
Bowman’s capsule and glomerulus are referred to as renal (or
Malpighian) corpuscle. The renal corpuscle filters blood via
specialized cells that respond to physiological cues. Glomeru-
lar capillaries are fenestrated, that is have pores which allow
fluids and small molecules such as ions and sugars to leave
the blood and, instead, retain cells and proteins exceeding
pore size, complexes of carrier proteins and lipids, as well
as calcium ions (Ca2+). Wrapped around the capillaries and
with characteristic protrusions called foot processes which
contact the capillary’s basement membrane are podocytes,
specialized epithelial cells integral to the filtration barrier [6–
8]. Adjacent foot processes are separated by slit diaphragms
about 14 nm wide with 30–50 nm wide pores carrying out fil-
tration [6] (Figure 1).Major components of the slit diaphragm
include members of the nephrin protein superfamily and
NEPH1, which are coexpressed and form the diaphragm via
homotypical and heterotypical interactions [6]. Together, the
basementmembrane, slit diaphragm, and podocyte processes
form a barrier between plasma and filtrate which is essential
to glomerular function. Its disruption can lead to kidney
disease [9]. Differences in pressure between the glomerulus
and Bowman’s capsule determine the glomerular filtration
rate (GFR, the amount of filtrate produced per minute),
which is used to measure kidney function. Because ion
and fluid balance depend on flow efficiency, glomerular
filtration rate is subject to multiple regulatory mechanisms.
The glomerular filtrate is first collected in the Bowman’s
capsule and directed through the nephron, flowing through
the proximal convoluted tubule and the descending and
ascending branches of the Loop of Henle, rising through the
distal convoluted tubule while being modified, and, finally,
arriving to the collecting duct as urine (Figure 2).
2.1. Human Nephron Development. Mammalian nephrons
formduring the late embryonic and early postnatal stages and
display limited cell turnover, resulting in low regeneration
rate in the adult [10]. Interactions between two mesoderm-
derived tissues, the ureteric bud (UB), and the adjacent
metanephric mesenchyme (MM) initiate nephrogenesis [10].
In part driven by developmental regulators Ret, Gfra1, Wnt11,
Wnt6, and Pax2 in the UB and Bmp4, Gdnf, Pax2, and Wt1
in the MM, the UB invades the adjacent MM, generating the
collecting duct [10–16]. The UB then branches to form a T
shape within the MM. The two ends of the T structure then
induce formation of the cap mesenchyme, which contains
nephron stem cells and progenitors, as well as stromal cells
that support kidney ontogenesis by producing signaling
molecules, for example retinoic acid, promoting expression
of Ret, ERK, MAPK, PI3K, PLC, andWNT [14, 17–20] in the
UB.The iteration of this process produces both the branched
structure of the ducts and nephron multiplicity. The MM
cells then aggregate and, responding to Wnt signaling [21],
undergo mesenchymal-to-epithelial transition to produce
the renal vesicle or nephron progenitor [10–13]. Vesicle
cells polarize, first establishing a proximal-to-distal axis [22]
followed by an apical-basal one [23, 24]. After polarization,

















































Figure 2: Schematic features of a generalized human nephron. The glomerulus, the different regions of the nephron, and corresponding ion
and solute transport are indicated. The dashed arrows depict direction of the fluid flow.
the renal vesicle reshapes in the form of a comma, then
that of an S, and fuses with the UB, while cells differentiate
morphologically [10, 25]. The S-shaped body gives rise to
the glomerulus, Bowman’s capsule, and both proximal and
distal tubules. The intermediate region of the S-shaped body,
instead, yields the loop ofHenle [26].Mesangial cells, integral
to the glomerulus, derive from the stromal cells [15, 27].
Finally, the vasculature is formed by mesodermal cells that
migrate into the developing kidney [28].
3. The Drosophila Renal System
In the fly, filtration is carried out by specialized cells called
nephrocytes, which display remarkable similarities to the
human podocytes [6]. Nephrocytes were originally discov-
ered in the 1800s and found to uptake and store multiple
compounds, including silver nitrate, albumin, and dyes [29–
34]. Nephrocytes are found in two clusters: one, called
pericardial, near the tubular heart and the other, called
garland, harboring two nuclei, close to the esophagus [6, 32–
36]. Drosophila nephrocytes display characteristic in-folding
of the plasma membrane which form channels flanked by
foot processes [6]. Ultrastructural studies have revealed
that nephrocytes form a three-layered filter morphologically
similar to that formed by the vertebrate podocytes [6, 32–34,
36, 37]. Like human podocytes, pericardial nephrocytes filter
and reabsorb solutes from the Drosophila circulating fluid,
called haemolymph, via channels regulated by 30 nmwide slit
diaphragms [38–40]. Slit diaphragms feature two filaments
composed of proteins encoded by genes sticks and stones
(sns) and dumbfounded (duf, also called kirre), a NEPH1
ortholog [6]. Other protein components of the nephrocyte
slit diaphragm include the products of genes mec-2, a
podocin ortholog, and pyd, a ZO-1 ortholog [6]. Alike human
podocytes, a basement membrane enwraps each nephrocyte.
Together, the nephrocyte diaphragm and the basementmem-
brane form the filtration barrier inDrosophila, the integrity of
which is maintained by protein-protein interactions between
orthologs of the human slit diaphragm proteins (Figure 1).
The filtrate is actively endocytosed from the sides of the
channels, retained in cell vacuoles and either broken down
(proteins) or stored (toxins, silver nitrate) [41]. The recent
findings that nephrocytes may be apicobasally and baso-
laterally polarized reinforced their similarity with human
podocytes [42, 43]. Moreover, nephrocytes and podocytes
appear to respond similarly to pharmacological treatment.
Administration of puromycin [44] and protamine sulfate [42]
was found to disrupt the filtration barrier. Because of their
extensive functional overlap with the necessary podocytes,
the discovery that nephrocytes are, instead, dispensable in the
adult fly, yet necessary for larval survival [45], was surprising
and future studies are being targeted to understand this
apparent paradox.
Nephrocytes have been used to model human nephrotic
syndromes, in which podocyte processes are effaced as a
consequence of mutations in the genes encoding for slit
diaphragmproteins. Because thesemodels have been recently
reviewed, we refer interested readers to [46].
3.1. Malpighian Tubule Morphology. In Drosophila two pairs
of MTs are made of a single-layered epithelium and depart
from the interface between mid- and hind-gut (Figure 3).
With one tubule residing more anteriorly and the other more
posteriorly within the abdominal cavity, the MTs are folded
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Figure 3: Schematic features of the Drosophila Malpighian tubules. The anterior and posterior tubules with relative functional segments and
ion and water transport are indicated. Dashed arrows depict the direction of the fluid flow. Features and functions of principal and stellate
cells are shown (below).
in a stereotypical way, which is thought to ensure efficient
metabolic waste removal and osmoregulation in the open
circulatory system typical of insects. Unlike the mammalian
closed circulatory system in which the circulating fluid is
subject to glomerular ultrafiltration,Drosophila haemolymph
is, instead, filtered. Also different from the mammalian
nephrons that are embedded in organ tissues, the twoMTs are
free inside the fly’s body cavity and can be cleanly microdis-
sected. Anterior and posteriorMTs can be distinguished both
functionally and morphologically, because of their distinct
transcriptomes and the anterior tubule being longer [47].
The anterior tubule pair can be divided into four sections:
initial, transitional, main, and terminal (Figure 3). These
regions contain type I cells, known as principal cells, and
type II cells, known as stellate cells (Figure 3). Principal cells
arise from a key interaction between the midgut and the
hindgut, constitute about ∼80% of all tubule cells, and are
responsible for the transport of cations and organic solutes
[48]. Stellate cells are scattered around the principal cells and
are responsible for water and chloride ion (Cl−) flow [48, 49].
Reducing tubular expression of the vacuolar- (V-) ATPase
by using fruit flies heterozygous for a lethal insertion in the
gene encoding for the V-ATPase beta subunit revealed that
cation transport may solely be performed by principal cells
[50]. Stellate cells were only found in secretory regions and
were absent from reabsorptive regions, suggesting that they
may have secretory roles [50]. The cells in the MT initial
segment are thinner and may excrete specifically Ca2+ ions
at high rates [51]. Cells of the terminal segment appear to
regulate ion and water balance via selective readsorption
from and secretion into primary urine and by removing
nitrogen-containing catabolites from the haemolymph via
active transport of uric acid to the tubule lumen and passive
diffusion of other molecules through the intercellular spaces.
As the primary urine is transported along the tubule, it
is sequentially transformed, a process that requires both
apicobasal cell polarization of the tubular epithelium and
planar cell polarity. Tubular cells were found to be func-
tionally differentiated in a proximal-to-distal fashion and the
processed urine is eventually secreted by the more distal
cells. Because of their fundamental role in detoxification, the
normal development of MTs is essential in the fruit fly.
Just like human nephrons, Drosophila MTs exhibit inter-
nal marked asymmetry which corresponds to distinct spatial
domains of gene expression [50, 51]. Analyses of enhancer
trap expression in the MTs revealed that the initial, tran-
sitional, and main segment of the anterior tubules and the
sole main segment in the posterior tubules correspond to
different cell types and distinct physiological functions [50].
The main segment was found to secrete potassium chloride
(KCl) and water at high rates [52] and the lower third of
the tubule carried out reabsorption [50]. The lower regions
of the MTs appeared to modify the travelling fluid from the
main segment by reabsorbing potassium ions (K+) [53] but
not water [54], contrary to what was previously reported
[50]. Moreover, the lower tubules were found to acidify the
fluid and transport Ca2+ into the lumen (Figure 3) [53].
Remarkably, in just about 15 seconds, the cells located in
the main segment of the Drosophila MTs were found to
secrete fluid in amounts equal to their own volume, making
the MTs the fastest known filtering system [52, 54]. While
the observed functional complexity of the MTs was initially
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found surprising and in apparent contradiction with its
reputation as a simplified epithelial developmental model
[50], this same functional complexity turned out to be an
asset for modeling human renal disease in combination with
the available genetic and technological tools for probing ion
transport [52].
3.2. Ion Transport and Fluid Secretion in the Malpighian
Tubules. In the MTs, multiple ion transporters regulate ion
balance in different sections. An apical V-ATPase gener-
ates a primary proton gradient that fuels the activity of
sodium/proton (Na+/H+) and K+/H+ exchangers, also api-
cally localized, which release Na+ and K+, respectively, in the
lumen [54]. K+/Cl− cotransporters localized at the basolateral
membrane [55] decrease K+ concentration in the secreted
fluid as it passes through the lower tubule [53]. Channels
found in stellate cells transport Cl− from the haemolymph to
the lumen and are under control of the leucokinin peptide-
hormone family [49, 54]. Leucokinins are synthesized in
response to increased intracellular Ca2+ and promote both
fluid secretion and epithelial permeability to Cl− [56].
Cardioacceleratory neuropeptide CAP2b was found to
stimulate fluid secretion specifically via cyclic GMP (cGMP)
and to activate the nitric oxide (NO) signaling pathway
[52, 57] that regulates salt and water balance in the fly
MTs [58]. Early studies tested if increased concentration of
intracellular Ca2+ could stimulate CAP2b and activate the
NO/cGMP pathway in different cell types [59]. Producing the
first Ca2+ reporter system in DrosophilaMTs, Rosay and col-
laborators expressed aequorin, a Ca2+-sensitive luminescent
protein, in principal cells in the tubule main segment via the
GAL4/UAS binary expression system [59, 60]. As aequorin
was produced in the tubules in vivo, luminescence indicated
both the amount of aequorin and Ca2+ amounts. Stimulation
of CAP2b-dependent physiological responses caused rapid
Ca2+ release from internal stores [59]. Because in this system
noCAP2b stimulationwas observed in stellate cells, principal
and stellate cells of the main segment are unlikely to be
connected through gap junctions [59].
3.3. Malpighian Tubule Development. TheMTs start forming
as four primordia derived from the hindgut primordium
and visceral mesoderm in the six-hour embryo [4, 61] in a
process requiring the gap gene product Kru¨ppel (Kr) and
the transcription factor Cut [48, 62, 63]. The specification of
future tubule cells is determined via Kr [48] and, similar to
mammalian kidney development, the Wnt pathway [10, 48].
Each tubule primordium contains a unique tip cell
specified by lateral inhibition via the Notch pathway [4,
48, 64]. The tip cell segregates and activates the Epidermal
Growth Factor receptor homolog DER [65] which promotes
cell proliferation, tubular growth, and development of the
MTs excretory system [64, 65]. As the MTs grow closer to
the caudalmesoderm they inducemesenchymal-to-epithelial
transition in nearby cells that will insert themselves in the
tubules and become stellate cells [4]. The ectoderm-derived
tubular epithelium is formed of principal cells [4] and the
ureter of ectodermal cells [4]. Cells divide a definite number
of times to give rise to 146 principal and 33 stellate cells in
each anterior tubule and 105 principal and 22 stellate cells in
each posterior tubule in Drosophila [50, 66]. Most of tubule
ontogenesis is completed during embryogenesis, and theMTs
are not histolysed during metamorphosis. Using positively-
marked mosaic lineage with GFP-labeled proliferating cells
enabled the discovery of multipotent adult stem cells in the
lower tubule and ureter [4]. Such cells require JAK-STAT
signaling for self-renewal and are analogous to stem cells
activated during repair of kidney ischemic injury [4].
3.4. Immune Function of the Malpighian Tubules. The MT
epithelium is part of the fly’s defenses against pathogens.
The MTs display innate immunity with both humoral and
cellular responses and no adaptive response, as is typical
for insects [67, 68]. Remarkably, studies in Drosophila first
revealed the immune function of Toll-receptor signaling
[69]. In fact, the Toll gene, originally identified for its
function in embryonic polarity [70], was later found to
function in immunity [71] and to have a few homologs in
the fly, including “18-wheeler” [72] and multiple vertebrate
ones dubbed Toll-Like Receptors (TLRs). Unlike other fly
organs involved in immunity, the MTs display constitutive
production of antimicrobial peptides (AMPs) [73]. Upon
sensing infection, the MTs activate distinct pathways when
triggered by specific pathogens. The Toll pathway was found
to respond to fungal and Gram-positive bacterial infections
and the immune deficiency (IMD) pathway to respond to
Gram-negative bacterial infections [74, 75]. MTs may also
initiate a Toll-independent humoral response [76]. All these
eventually trigger release of seven groups of AMPs, either
directly from theMTs [73] or indirectly from the fat-body, the
latter being the fly liver-equivalent [68, 69, 77]. The groups
of AMPs, Drosomycin, Metchnikowin, Defensin, Attacin,
Cecropin, Drosocin, and Diptericin, appear to inhibit growth
of haemolymph-invading microorganisms [77]. Both the
IMD and Toll pathways were found to sense superficial
peptidoglycan on the bacterial cell wall via signaling by
peptidoglycan-recognition proteins (PGRP) in theMTs prin-
cipal cells and gut [69, 78, 79]. PGRP function has mainly
been studied in the gut [80], yet the pathway appears to func-
tion similarly in theMTs.The Toll proteins display homology
to the cytoplasmic domain of the vertebrate interleukin 1
receptor and participate into similar intracellular signaling
cascades [81]. The IMD pathway is considered to be equiv-
alent to the vertebrate TNF pathway [75]. Both Toll and IMD
pathways result in activation of NF-𝜅B-like transcription
factor Relish and induce transcriptional changes [82].
The steroid hormone ecdysone that regulates principal
and stellate cell fluid secretion [68] also affectsMT-dependent
immunity. Ecdysone may promote haemocyte proliferation
and fast pathogen encapsulation [83]. In S2 cells, ecdysone
was also found to induce transcription of the PGRP-LC gene
encoding the peptidoglycan receptor and, independently, of a
subset of AMPs [84]. Ecdysone also triggers histolysis during
metamorphosis [83]. However, the MTs are resistant to this
process, possibly due to their fundamental role in immunity.
Diap2, an antiapoptotic protein, was also found to contribute
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to the innate response in the IMD pathway, possibly via
regulation of MT ion channels [85]. Diap2 levels increased
in the MTs when there was an immune threat; conversely,
decreased Diap2 made flies more prone to infections [85].
Finally, upon septic infection, the MT-dependent
immune response may alternatively be activated via the NO
pathway, which in turn initiates the IMD pathway and leads
to increased NO Synthase (dNOS) and improved fly survival
[67, 68].
With growing appreciation for the importance of the MT
immune function, the ongoing mechanistic studies of gut-
mediated immunity will provide resources and paradigms
to better define the role of the MTs in the defense from
pathogens.
4. Malpighian Tubules to Model Disease
MTs have been utilized to study the physiology of fluid trans-
port because of their anatomical accessibility, streamlined
anatomy, and one-cell-thick epithelium. In MTs, the prolifer-
ation of the founder cells (anlage), their spatial organization,
patterning, and differentiation occur in sequence, rather than
concurrently as in other epithelia, enabling studies of separate
stages in time course experiments. MTs and mammalian
nephrons share functionally distinct regions (Figures 2 and
3), analogous functions, and display remarkable transcrip-
tome conservation [47, 86]. For example, similar to mam-
malian renal tubules, MTs carry out detoxification thanks
to high levels of cytochrome P450 and glutathione trans-
ferase [87]. Likewise, mutations in evolutionarily conserved
V-ATPase subunits were initially discovered in Drosophila
because of their renal phenotypes [88, 89]. Three years later,
equivalent mutations in the human ATP6B1 V-ATPase were
reported to cause similar defects in patients [90]. As the
interest in modeling renal function in the fly continues to
grow, we review some of the successful examples below.
4.1. Nephrolithiasis. Drosophila has been used to model the
most common kind of human kidney stones, namely, calcium
oxalate nephrolithiasis [91]. Nephrolithiasis refers to the
formation and movement of kidney stones in the urinary
tract [91]. There are multiple types of kidney stones that
are distinguished for their different composition and origin.
Largely dependent on diet and metabolism, kidney stones in
the urinary tract are most commonly composed of calcium
oxalate (CaOx) and, in lesser quantities, calcium maleate or
phosphate. Also dependent on diet and metabolism, cysts
composed of uric acid develop when urine is too acidic, for
example in severe dehydration, gout, or following chemother-
apy. Struvite cysts are caused by kidney infections and may
result in urinary obstruction [91]. Finally, cystine stones form
as crystals of leaked cystine in rare cystinuria patients. While
rats had been the model of choice for CaOx stone formation
[92], prohibitive costs of breeding and caring inspired Chen
and colleagues [92] tomodel nephrolithiasis in the fly. Similar
to rodents, flies appeared to respond to oral administration
of lithogenic agents ethylene glycol, hydroxyl-L-proline, and
sodium oxalate, by inducing formation of CaOx crystals
in the MTs between two and three weeks after ingestion.
Importantly, response severity was dose-dependent [92].
Recently, RNAi-mediated knockdown of the enzyme
xanthine dehydrogenase (Xdh) in the fly was shown to induce
ectopic calcification and accumulation of crystals and stones
in theMTs [93].Well-fed Xdh-knockdown flies only survived
three days, as opposed to 60 days of the wild type control.
Chemical analysis of the stones by micro X-ray fluorescence
revealed significant amounts of Ca2+ and zinc (Zn). Because
the latter had never been involved in kidney stone formation
before, genetic confirmationwas obtained byRNAi-mediated
inhibition of Zn transporters in the fly, which was found to
decrease stone formation [93]. Dietary and pharmacologic
modulation of Zn levels in the fly and analyses of human
kidney stones further confirmedZn as a bona fide component
[93]. In this case, theDrosophilamodel enabled the discovery
of a new contributor to nephrolithiasis and indicated Zn-
metabolic enzymes as potential therapeutic targets [93]. One
issue to be clarified is that dietary Zn intake has been
linked to increased risk of kidney stones in the adult (yet
not in adolescent) individuals, while inhibiting Zn excretion
was found to reduce cyst formation in the fly. One of the
possible ways to interpret these apparently contradicting
results posits that Zn may promote formation of different
crystals depending on concentration [94] and indicates the
need to probe additional physiological parameters in future
studies to capture the complexity of kidney stone formation.
Flies have been used to study the processes leading
to formation of uric acid stones because of their high
levels of urate crystals normally accumulating in the tubule.
Systematic analyses of the 33 genes encoding for subunits
of the V-ATPase, some of which with multiple isoforms,
revealed that mutants in the genes encoding core V-ATPase
subunits displayed transparent MTs as a result of urine
acidification, which decreased uric acid crystallization [89].
Notably, similar acidification defects were also found in
patients with mutations in two V-ATPase subunits, which
suggests a certain degree of functional conservation [90, 95].
4.2. Polycystic Kidney Disease. Polycystic kidney disease
(PKD) is a genetic disease affecting at least 12.5million people
world-wide, regardless of ethnicity [96]. Two forms of PKD
exist, one autosomal dominant (AD) and one, rarer and
more severe, which is autosomal recessive (AR) [96] and will
not be discussed here. ADPKD causes the development and
progressive enlargement of fluid-filled cysts in the nephron,
that consequently increase kidney size and cause interstitial
fibrosis and chronic kidney disease by age 55 [96]. In half
of the patients the severe damage results in kidney failure,
making dialysis or renal transplant the only treatments [96].
The lack of a cure and dialysis costs that can surpass 150,000$
per patient per year [1] make PKD a global priority.
Genetic Underpinning of PKD. More than 85% of ADPKD
patients carry mutations in the PKD1 gene, which encodes
polycystin-1, a G-protein coupled receptor (GPCR) [97].
Complete mutational inactivation of both alleles is rare
and lethal pre- or peri-natally [96]; however, incompletely
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penetrant PKD1 alleles have been found in homozygosis
[98]. Mutations in another gene, PKD2, are found in about
10% of ADPKD cases [97]. PKD2 encodes polycystin-2, a
transmembrane calcium channel of the TRPP family which
was found to physically interact with polycystin-1 [99, 100].
The remaining ∼5% of ADPKD patients carry unknown
mutations other than PKD1 or PKD2 [101]. Because of
their clear implication in PKD etiology, PKD1 and PKD2
genes and corresponding polycystin-1 and polycystin-2 gene
products are being studied in much detail. Polycystin-1 and
polycystin-2 complexes were found to mediate cell-matrix
and cell-cell interactions, planar cell polarity, signal trans-
duction, and cilia-mediatedmechanosensation [96].We have
recently reported that cystic tissue from ADPKD patients
carrying a PKD1 mutation exhibited significant reduction
of the Bicaudal C (BICC1) gene expression [102]. Similarly,
Pkd1−/− mice displayed reduced Bicc1 protein specifically
in the kidneys [102], placing BICC1 genetically downstream
of PKD1. Mutations in the BicC gene of many vertebrates,
including humans, cause the development of renal cysts [103–
110]. BicC was originally discovered in the fly during a screen
for embryonic polarity determinants in the germline [111].
Cyst formation is complex and unfolds over time.
ADPKD patients carrying PKD1 or PKD2 mutations already
display small renal cysts at birth [96] yet remain asymp-
tomatic until middle age because the renal capacity is in vast
excess (in fact, donation of one kidney is compatible with
life). After then, kidney function declines rapidly. Because
polycystin-1 and polycystin-2 are part of multiple protein
complexes with wide cellular distribution, dysregulation of
either in the renal tubule affects many pathways, including
apicobasal and planar cell polarity, cell proliferation, cell
metabolism, fluid secretion, and the extracellularmatrix [112–
115]. In PKD cysts form in the renal tubular epitheliumwhere
some cells reactivate normally quiescent proliferation path-
ways and begin to divide. In parallel, epithelial polarization
is progressively lost, impacting secretion. Fluid accumulation
in the cysts, in turn, stimulates further cell division, possibly
in response to increased tensional stretch in the tissue [116,
117]. It is currently unclear what triggers cyst formation. As
cysts expand, tubular cells display activation of various signal
transduction pathwaysmediated byCa2+ and cAMP, e.g., Raf-
MEK-ERK [118, 119], the mammalian Target of Rapamycin
(mTOR), PI3-kinase-Akt, JAK-STAT, NF-kB, Wnt, Hippo,
and G-proteins [115, 118–130]. In spite of the enumeration
of these pathways, the mechanisms of cyst initiation and
progressive cystic degeneration remain largely unknown,
likely because of the anatomical complexity of the vertebrate
kidney and slow disease onset, which hinder experimental
probing.The BicC fly provided the first account of renal cysts
in Drosophila [102]. Modeling PKD in the fly may enable
biochemical characterization of the cystic tubule and define
the genetics of cyst formation and progression due to low
genetic redundancy, and may advance our understanding
of the core cystic processes. BicC encodes a conserved
cytoplasmic RNA-binding protein with orthologs in many
species [104, 105, 109, 131–133]. BicC can bind to multiple
mRNA targets and appeared to reduce their expression
posttranscriptionally [134]. The resulting target upregulation
in the oocytes from heterozygote BicC female flies was found
to disrupt anterior-posterior embryonic polarity [7, 115–
135], while BicC homozygotes displayed oogenesis arrest at
stage 10 [136]. Similar to ADPKD patients, BicC mutant flies
featured fluid-filled cysts in the MTs already at hatching;
over time the cysts enlarged and became more numerous
[102]. Compared to wild type, BicC flies were short-lived,
possibly a consequence of their defective renal function
[102]. BicC MTs also displayed extra branches, indicating
underlying developmental and polarity defects. Oocytes
from BicC mutant flies exhibited abnormal actin structures
which prevented secretion of the dorsal fate determinant
Gurken [137–141]. Similarly, the BicC proteinwas required for
epithelial polarization via cadherin-mediated cell adhesion
in the IMCD murine kidney cell line [142]. Initial molecular
analyses of the BicC MTs identified the activation of the myc
and TOR pathways, two hallmarks of vertebrate PKD [102].
Like ADPKD patients, postrenal transplantation (in which
diseased kidneys are left in place) and administration of the
immune suppressant and TOR inhibitor rapamycin could
transiently rescue the BicC flies and reduce cysts, relative to
untreated controls [102, 126].Murine PKDmodels also exhib-
ited mTOR cascade stimulation [143–148] and responded
to rapamycin by delaying cystic onset [126, 145, 149]. In
sum, the BicC cystic flies appeared to recapitulate many
of the diseased features of PKD, displayed pharmacological
response to rapamycin [102], and may be a valid model to
advance our understanding of the molecular bases of renal
cyst formation and the formation of extra tubular branches.
One interesting aspect is that ciliary (dys)function appears
prominent in vertebrate PKD [150]. The absence of ciliated
epithelia in Drosophila raises the intriguing question of how
cysts form and develop in BicCMTs versus human nephrons.
Considering that other ciliary pathways, e.g., hedgehog, were
originally discovered in the fly, the striking biochemical
similarities between PKD-type cysts and the BicC-dependent
cysts in the fly may not be as surprising and may suggest new
hypotheses on the evolution of ciliary function.
With proper consideration of the differences between flies
and humans and of the hierarchical relationship between
the BicC and PKD1 genes, the BicC cystic fly may offer
opportunity to chart conserved pathways that are altered
in BicC mutation, are relevant for cyst formation and/or
progression, may allow to form new hypotheses on BicC
function and disease mechanism, and contribute to our
understanding of the larger functional context of human
PKD. Considering that BicC was also found in a protein
complex linked to human nephronophthisis, another cystic
kidney disease [110, 133], future studies will reveal if BicC
function may affect multiple pathways of renal cystogenesis.
5. Conclusion
The remarkable conservation of renal functions between fruit
flies and humans is suggestive of the presence of strong
evolutionary constraints imposed on the detoxification pro-
cess of all organisms. Emerging evidence of the interplay
between renal and immune functions suggests additional
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requirements for the renal system. Multiple diseases causing
progressive degeneration and loss of function of the kidney
result in organ damage that may only be remedied by renal
replacement therapy or dialysis, which are costly socially
for the health care system and personally to the patients
and their families, due to their negative impact on quality
of life. Studies aiming at understanding the mechanisms
of renal disease have been hindered by the anatomical
complexity of the mammalian kidney. Drosophila possesses
an evolutionary intermediate between glomerular and non-
glomerular renal system, consisting of anatomically separated
renal tubules and nephrocytes that, together, fulfill the renal
functions. Similar developmental origin of the fly MTs and
nephrocytes with their human counterparts, the nephron and
the glomerular podocytes, respectively, is accompanied by
conserved cellular pathways. Making the fruit fly a useful
model to study the mechanisms of disease, the structurally
streamlined, anatomically isolated, renal structures can be
easily microdissected and studied biochemically; moreover,
they can be probed genetically utilizing the vast array of
Drosophila genetic tools. In multiple cases in which human
renal disease has been modeled in Drosophila, including
nephrolithiasis and PKD, the conservation seemed to extend
to pharmacological responses, echoing similar examples in
other fly diseasemodels. Considering thatmany drug binding
sites were found to be conserved in the fly [151], development
of proper pharmacological screen protocols in the fly may in
future provide a rapid and effective alternative strategy for
drug discovery.
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